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Characterization of TRAPP interacting proteins FLJ13611 and SPATA4 
Débora Teixeira Duarte 
The mammalian TRAPP complex is a multi-subunit tethering factor acting in 
vesicular transport between the endoplasmic reticulum and the Golgi apparatus. Here we 
describe two novel interactors of this complex, FLJ13611 and SPATA4. FLJ13611, a 
previously uncharacterized protein, was shown to interact with TRAPP components by 
yeast two hybrid, co-immunoprecipitation and in vitro binding, and was shown to co-
fractionate with TRAPP by size exclusion chromatography. FLJ13611 depletion by siRNA 
caused the Golgi apparatus to fragment, indicating its importance in maintenance of Golgi 
structure. Moreover, FLJ13611 was found to interact with the Golgi stacking proteins 
GRASP55 and GRASP65 by yeast two hybrid, co-immunoprecipitation and in vitro 
binding. We propose FLJ13611 is a new component of the mammalian TRAPP complex 
which should be called TRAPPC13. SPATA4, a spermatocyte-specific protein of unknown 
function, was identified in a yeast two hybrid screen using TRAPPC2 as a bait. It is present 
in both nuclear and cytosolic compartments and it interacts with the TRAPPC2 portion of 
the TRAPP complex. SPATA4 contains a domain of unknown function called DUF1042 
domain, which is necessary but not sufficient for the interaction with TRAPPC2. We also 
show by in vitro binding that the presence of the two C-terminal helices of TRAPPC2 is 
required for the interaction and the interaction is stronger when TRAPPC2 is in its 
heterotrimeric form. Our results suggest a role for SPATA4 in membrane traffic and a 
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1.1 Membrane trafficking and the Golgi apparatus 
Membrane trafficking is central to eukaryotic cells and describes the process of 
delivering proteins and lipids to various intracellular locations and to the extracellular space by 
using membrane-delimited carriers (vesicles). This process consists of three main steps, (i) the 
budding of a vesicle from the donor compartment, (ii) translocation of the vesicle to the 
destination compartment, and (iii) vesicle fusion with the acceptor compartment. Nearly all 
forms of membrane transport, including exocytosis, endocytosis and retrograde transport occur 
through vesicles (Bonifacino and Glick, 2004).  
Most secreted proteins, after properly folding in the endoplasmic reticulum (ER), 
are packaged into coat protein complex II (COPII) coated vesicles that bud from ER exit-sites 
and are delivered to the Golgi apparatus (Hughes and Stephens, 2008). After being processed in 
the Golgi, they are packaged into carriers that bud from the trans-Golgi network in a process 
controlled by the four-phosphate adaptor proteins 1 and 2 (FAPP1 and FAPP2) and the small 
GTPase ADP ribosylation factor (ARF). Then, the carriers travel toward the plasma membrane, 
where fusion occurs, ultimately releasing the protein to the extracellular environment (Godi et 
al., 2004). 
The Golgi apparatus is not only the central axis of the membrane trafficking system, 
but also a signaling platform and the site for lipid and carbohydrate biosynthesis and post-
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translational modifications of proteins (glycosylation, phosphorylation and sulfation). The set of 
glycosyltransferases that reside in Golgi cisternae make possible glycosylation events 
significantly more complex than those in the ER, which are thought to be merely facilitators of 
protein folding. Glycosylation at the Golgi allows further functional diversification of mature 
proteins, adding a spectrum of novel functions especially important in adaptive and innate 
immune responses. In addition, the Golgi apparatus has a role in determining cell polarity in 
secretory cells by guiding the exocytic traffic toward a specific part of the plasma membrane as 
well as in migrating cells, which is accomplished by adding new membranes to the leading edge 
(Shorter and Warren, 2002). 
Although its function is highly conserved among eukaryotes, Golgi morphology can 
vary substantially between different species. In mammals, the Golgi apparatus is composed of a 
large number of membranous flattened cisternae, organized in stacks, which are linked by 
tubular bridges (non compact zones), resulting in the formation of a ribbon in the perinuclear 
region near the centrosome (Colanzi et al., 2003; Wei and Seemann, 2009). This localization 
allows a close association to microtubules (MT), which are essential for membrane trafficking 
in higher eukaryotes. In addition, MTs help to maintain the structure of the Golgi, since 
depolymerisation of the MT network leads to disruption of the Golgi structure (Rios and 
Bornens, 2003).  
In plants and Drosophila, the Golgi stacks are not linked, but found dispersed 
throughout the cytoplasm and each one is associated with an ER exit site. In Saccharomyces 
cerevisiae, the Golgi cisternae appear dispersed in the cytoplasm, while in the protozoa 
Toxoplasma gondii and Trypanosoma brucei only one stack is present (He, 2007). 
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In all the Golgi stacks three distinct functional regions have been identified, (i) cis 
Golgi network (CGN), where vesicles from the ER fuse to deliver their cargo, (ii) medial Golgi 
network, and (iii) trans Golgi network (TGN), where the content is sorted, packaged and sent to 
its final destination (Klumperman, 2011). 
 The Golgi receives and donates vesicles in both anterograde (ER to Golgi) and 
retrograde (Golgi to ER) directions, as well as to endosomes, lysosomes and other membrane-
bound organelles (Klumperman, 2011). Such variety of interconnected routes requires control 
mechanisms, either to ensure that the cargo reaches the right destination or to coordinate the 
fission (budding) and fusion of membranes. Indeed, many factors control membrane trafficking, 
including Rab GTPases, SNARE (soluble NSF attachment protein receptor) proteins and 
vesicle tethering factors (Cai et al., 2007).  
 
1.2 Tethering and vesicle fusion 
Tethering is defined as the first contact between a vesicle and its target membrane, 
which is mediated by “tethering factors”. Tethering factors can be either single polypeptides or 
multisubunit complexes, and they are found in a variety of locations, and act recognizing and 
capturing specific vesicles. As such, they are believed to provide the first layer of specificity in 
membrane trafficking. Some known multisubunit tethering factors are: TRAPP (transport 
associated protein particle) complex, that participates in the transport from ER to Golgi and 
between Golgi cisternae; Dsl1, that acts in transport from the Golgi to the ER,  COG (conserved 
oligomeric Golgi) complex, that acts in the retrograde transport of Golgi resident proteins, 
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HOPS (homotypic fusion and vacuole protein sorting), CORVET (class C core vacuole / 
endosome tethering complex) and GARP (Golgi associated retrograde protein) complex  
(Angers and Merz, 2011). 
Rab proteins are usually synthesized as soluble proteins, and are inserted into 
membranes after the addition of geranylgeranyl groups to their C-terminus. During tethering 
events, inactive Rab proteins already inserted in the membrane become active by exchanging 
guanosine diphosphate (GDP) for guanosine triphosphate (GTP). The Rab can then recruit 
effectors at the membrane, which will act in events upstream of vesicle fusion. Different Rabs 
are found in different compartments, ensuring an additional layer of specificity (Hutagalung 
and Novick, 2011).  
After tethering occurs, vesicles are thought to uncoat, and at some point following 
uncoating, vesicle SNARE (vSNARE) binds to the target SNARE (tSNARE), bringing the 
membranes closer, so that the leaflets can ultimately fuse. Several pairs of SNAREs have been 
described, and they also contribute to the specificity of membrane fusion (Bonifacino and Glick, 
2004). After the external leaflets fuse, there is the formation of a pore, which expands, allowing 
the contents of the vesicle to be released into the lumen of the target compartment 
(Chernomordik et al., 2006).  
In addition to physically capturing vesicles, some tethering factors can activate 
Rabs through guanine nucleotide exchange factor (GEF) activity, and may also play a role in 





1.3 TRAPP Complexes 
Transport protein particle (TRAPP) complex is a highly conserved multi-subunit 
tethering factor known to mediate ER-to-Golgi and intra-Golgi transport. First described in 
1998 by Sacher et al. as an 800 kDa protein complex localized to the cis-Golgi, the TRAPP 
complex is now thought to be present in at least three different forms in Saccharomyces 
cerevisiae (TRAPP I, TRAPP II and TRAPP III) and one in mammalian cells (Lynch-Day et al., 
2010; Sacher et al., 1998, 2001; Sacher and Ferro-Novick, 2001). 
In yeast, TRAPP I is composed of Bet3, Bet5, Trs20, Trs23, Trs31 and Trs33 
(Sacher et al., 1998). This forms a common core upon which the other two complexes are built 
by the addition of specific subunits for both TRAPP II (Trs65, Trs120, Trs130 and Tca17) and 
TRAPP III (Trs85). Although originally implicated in ER-to-Golgi transport, TRAPP I was 
recently suggested to be an in vitro artifact (Brunet et al., 2012). TRAPP II acts in the late Golgi 
trafficking (Sacher et al., 2001); and TRAPPIII is targeted to phagophore assembly sites, where 
it participates in autophagy-related processes (Lynch-Day et al., 2010).  
The mammalian TRAPP complex is composed of homologues of all yeast TRAPP 
subunits (except for Trs65, with no homolog found yet) named from TRAPPC1 to TRAPPC10, 
and the subunits TRAPPC11 and TRAPPC12, which have no homologues in S. Cerevisiae (see 




Table 1.1 Nomenclature of mammalian and yeast TRAPP subunits (adapted from Scrivens et 
al., 2011). 
Mammalian               Yeast 
Name Size (kDa)  Name Size (kDa) Complex 
TRAPPC1 17  Bet5 18 I, II, III 
TRAPPC2 16  Trs20 20 I, II, III 
TRAPPC2L 16  Tca17 16 II 
TRAPPC3 / 
TRAPPC3L 
20  Bet3 22 I, II, III 
TRAPPC4 24  Trs23 23 I, II, III 
TRAPPC5 21  Trs31 31 I, II, III 
TRAPPC6a / 
TRAPPC6b 
19 / 15  Trs33 33 I, II, III 
- -  Trs65 65 II 
TRAPPC8 161  Trs85 85 III 
TRAPPC9 140  Trs120 120 II 
TRAPPC10 142  Trs130 130 II 
TRAPPC11 129  - - - 
TRAPPC12 79  - - - 
The following subsections will discuss yeast TRAPP complexes (1.3.1), the 
particularities of the mammalian TRAPP complex (1.3.2) and information about TRAPP 
proteins in other species (1.3.3). 
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1.3.1 Yeast TRAPP complexes 
Despite being classified as a tethering factor, there is no direct evidence that 
TRAPP can bridge the vesicle and the target membrane. The idea of TRAPP as a tether came 
from the fact that TRAPP mutants show vesicle accumulation (Rossi et al., 1995; Sacher et al., 
2001). However, vesicles can accumulate for many different reasons and not only due to a 
defect in tethering. Any block in the trafficking process after the vesicle buds could, in theory, 
lead to this phenotype. Interestingly, yeast TRAPP I is a GEF for the small Rab GTPase Ypt1 
(Wang et al., 2000), which controls ER-to-Golgi and intra-Golgi trafficking, and this could 
explain the phenotype observed in TRAPP mutants even if TRAPP is not a tether. Likewise, 
yeast TRAPP II is a GEF for Ypt31/32 (Jones et al., 2000; Zou et al., 2012), a GTPase that 
functions in Golgi-to-plasma membrane and endosome-to-Golgi transport. 
Localization studies performed on yeast TRAPP subunits have been controversial. 
Initially,  Bet3 was found only in cis-Golgi membranes (Sacher et al., 1998). Conversely, Trs33 
(Tokarev et al., 2009), Trs65, Trs120, Trs130 were seen mainly in the trans-Golgi (Cai et al., 
2005; Liang et al., 2007). Whereas Trs65, Trs120 and Trs130 are TRAPP II-specific subunits, 
Bet3 and Trs33 are part of all TRAPP complexes, therefore they are expected to have a broader 
localization, and a fraction of them should certainly co-localize with Trs130. These conflicting 
results could be attributed to the use of different tags (GFP, YFP, etc) and their position (C-
terminal or N-terminal), as well as to different fixation methods. Alternatively, these data may 
suggest that the number of yeast TRAPP complexes is less than the three reported. Interestingly, 
the existence of a functional TRAPP I in yeast was recently questioned, and it is possible that 
functions attributed to it in ER-to-Golgi transport are actually performed by the autophagy-
8 
 
related TRAPP III complex. Trs85 mutants are defective in the cytosol-to-vacuole (CVT) 
pathway and Trs85 does colocalize with pre-autophagosomal structures, but the role of TRAPP 
III in autophagy might be indirect, derivative of its role in the early secretory pathway (Choi et 
al., 2011). A recent study using the v-SNARE Snc1 as a marker of intracellular transport 
suggested that Trs85 (a TRAPPIII specific subunit) acts in the ER-to-Golgi transport (Zou et al., 
2012).  
Corroborating this idea, biochemical studies have pointed to TRAPP I as an in vitro 
artifact, generated from TRAPP II and III in the presence of high salt concentrations. 
Interestingly, TRAPP I is absent in Trs23 mutants where the Saccharomycotina specific domain 
(SMS) is deleted, but no trafficking or growth defects are observed (Brunet et al., 2012). 
 
1.3.2 Mammalian TRAPP complex 
The mammalian TRAPP complex functions are similar to the ones attributed to 
yeast TRAPP I, participating in the early secretory pathway (Loh et al., 2005). It is reported to 
have GEF activity towards  Rab1, a small GTPase that regulates ER-to-Golgi and early Golgi 
trafficking, homolog of the yeast Rab Ypt1, although the activity does not appear to be as 
robust as that seen for the yeast complex on Ypt1p (Yamasaki et al., 2009).  
ER-to-Golgi trafficking in mammalian cells is, however, more complex than in 
yeast, due to the presence of the ER-Golgi intermediate compartment (ERGIC). The ERGIC, 
also known as vesicular-tubular clusters (VTC) or pre-Golgi intermediates, is localized in the 
vicinity of ER exit sites, and is formed by homotypic fusion of COPII coated vesicles derived 
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from the ER (Appenzeller-Herzog and Hauri, 2006). The mammalian TRAPPC3 protein has 
been shown to be required for ERGIC biogenesis (Yu et al., 2006), and TRAPPC12 partially 
colocalizes to this compartment (Scrivens et al., 2011). Moreover, depletion of either 
TRAPPC11 or TRAPPC12 leads to accumulation of cargo in ERGIC53 positive structures. 
Therefore, mammalian TRAPP seems to be involved in ER-to-ERGIC transport  (Scrivens et al., 
2011). 
Although only one TRAPP complex is found in mammalian cells, it might be 
present in numerous different subtypes that differ in the isoform of several TRAPP proteins 
they incorporate, including TRAPPC6 (present in at least three isoforms: two splice variants of 
TRAPPC6a, and TRAPPC6b), TRAPPC9 and TRAPPC3 . These isoforms could function in 
different places inside the cell or be expressed in different tissues, adding more complexity to 
vesicular transport in mammals (Kümmel et al., 2008). 
The association of TRAPP with membranes was suggested to be mediated by 
TRAPPC3. This subunit has a hydrophobic channel that could fit a myristate or other fatty acid 
and attach the complex to a lipid bilayer. In addition to this lipid anchor, the crystal structure of 
a mouse TRAPPC3 dimer reveals a flat and positively charged surface that could participate in 
non-specific electrostatic interactions with the negatively charged head groups of the 
phospholipids in the membrane (Kim et al., 2005). The yeast homolog, Bet3, seems to function 
in a similar way, since charge-inversion mutations in this flat charged surface lead to 




 Despite the fact that the mammalian cells do not have a separate “autophagy-
related” TRAPP complex like yeast (TRAPP III), many mammalian TRAPP subunits are 
somehow involved in autophagy-related processes. A proteomic analysis of the autophagy 
network in human cells identified TRAPPC5, TRAPPC8 and TRAPPC11 as required for 
autophagosome formation and TRAPPC12 as an inhibitor of the same process. Furthermore, 
these subunits, as well as TRAPPC2L, TRAPPC3 and TRAPPC4 interact with the tectonin 
beta-propeller repeat containing 1 protein (TECPR1), a component of the autophagosome 
assembly machinery (Behrends et al., 2010). 
TRAPPC2, in addition to its presence in the TRAPP complex, interacts with other 
proteins, apparently not related to secretion, such as the transcription repressor c-myc promoter 
binding protein 1 (MBP-1) (Ghosh et al., 2001). This interaction negatively regulates the 
transcription of the luteinizing hormone β (LHβ) gene in the pituitary gland (Ghosh et al., 2003). 
Other TRAPPC2 binding partners are the chloride intracellular channel proteins 1 and 2 
(CLIC1 and CLIC2) (Fan et al., 2003) and the nuclear protein associated with MRG 14 kDa 
(PAM14) ( Liu et al., 2010). 
Another mammalian subunit with roles outside the TRAPP complex is TRAPPC4, 
which is found to interact with the extracellular signal-regulated kinase 2 (ERK2), activating it 
and consequently regulating cell proliferation and apoptosis in colorectal cancer cells (Zhao et 
al., 2011). 
The mammalian TRAPP has also been reported to participate in ciliogenesis in 
retinal pigmented epithelium (RPE) cells, by targeting Rabin8 to the centrosome upon serum 
11 
 
starvation (Westlake et al., 2011). Rabin 8 is a GEF for Rab8, a GTPase required for the 
assembly of primary cilia (Nachury et al., 2007). The transport of Rabin8 to the centrosome 
also requires the participation of Rab11, the human homolog of Ypt31/32. Essentially, TRAPP 
and Rab11 recruit Rabin8 to the centrosome, and Rabin 8 activates Rab8 (Westlake et al., 2011). 
Whether the GEF activity of TRAPP towards Rab proteins is relevant in this process has not 
been addressed. 
 
1.3.2.1 TRAPP and diseases 
Mutations in TRAPP subunits have been linked to different diseases. Point 
mutations in TRAPPC2 are known to cause the X-linked skeletal disorder spondyloepiphyseal 
dysplasia tarda (SEDT) which results in a defect in endochondral bone growth (Gedeon et al., 
2001; MacKenzie et al., 1996). SEDT is characterized by the presence of flattened vertebral 
bodies and thick and short femoral necks, which is indicative of a defective endochondral 
ossification (MacKenzie et al., 1996). SEDT patients often develop premature osteoarthritis due 
to perturbations in the extracellular matrix of articular cartilage. At a cellular level, 
chondrocytes from SEDT patients have a reduced nuclear : cytoplasm ratio, abundant Golgi and 
dilated ER, suggesting a defect in secretion of matrix component (Tiller et al., 2001). 
TRAPPC2 is a broadly expressed protein; however, SEDT patients have no extra skeletal 
symptoms, which suggests the involvement of a second protein that would confer tissue 




Truncations in TRAPPC9 have been associated with autosomal-recessive mental 
retardation (Mir et al., 2009) and postnatal microcephaly (Mochida et al., 2009). Postnatal 
microcephaly in patients bearing TRAPPC9 mutations is characterized by diminished corpus 
callosum and cerebral white matter, indicating a role for TRAPPC9 in axon and dendrite 
growth (Mir et al., 2009). This role might be related to the activation of NF-kB, which is also 
involved in adult neurogenesis, by TRAPPC9. In mouse brains, TRAPPC9 is found in neurons 
of the cortical area, hippocampus and deep gray matter, and the expression increases with time, 
reaching its maximum in adult animals (Mochida et al., 2009). Therefore, TRAPPC9 seems to 
have a role in brain development. 
 
1.3.3 TRAPP complexes in other organisms 
In Drosophila, TRAPP II is required for cytokinesis in meiotic cells, where it is 
needed for constriction of the contractile ring and for recruiting Rab11 to the cleavage furrow. 
The Drosophila ortholog of Trs120, called brunelleschi (bru) collaborates with 
phosphatidylinositol 4-kinase β (PI4Kβ) and Rab11 in order to control the membrane addition 
to the cleavage furrow (Robinett et al., 2009). Surprisingly, mutations in the bru gene do not 
seem to affect mitotic cytokinesis in larval neuroblasts, indicating that the gene is required only 
for meiotic cytokinesis (Giansanti et al., 2004; Robinett et al., 2009). 
In Arabidopsis thaliana, TRAPP II seems to be important for the formation of the 
cell plate, a transient membrane compartment that appears during cytokinesis and is later 
converted into a cell wall.  Trs120 and Trs130 mutants show severe phenotypic defects, 
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including multinucleate cells, cell wall stubs, floating cell walls and vesicle accumulation, 
indicating a failure in tethering and/or fusion (Jaber et al., 2010; Qi et al., 2011; Thellmann et 
al., 2010). Nevertheless, these mutants show no defects in ER-to-Golgi or biosynthetic vacuolar 
transport (Qi et al., 2011). Cytokinetic defects are also seen in Arabidopsis TRAPP I mutants 
(Bet5, Trs31 and Trs33), although with milder phenotypes (Thellmann et al., 2010).  
In addition to a role in cytokinesis, Arabidopsis Trs120 and Trs130 are required for 
the delivery of the membrane transporter PIN2 to the plasma membrane (Qi et al., 2011), and 
confirming what is seen in yeast, Arabidopsis TRAPP II seems to be linked to Rab-A, which is 
a homolog of Ypt31/32, but not to Rab-D, a homolog of Ypt1 / Rab1 (Qi and Zheng, 2011). 
 
1.4 SPATA4 
Spermatogenesis associated protein 4 (SPATA4) was originally identified as a 
testis-specific apoptosis related gene (Liu et al., 2004a) expressed exclusively in testis in human, 
rat and chicken (Liu et al., 2004a; Liu et al., 2004b; Xie et al., 2007), but also found in ovaries 
of rainbow trout and zebrafish (Liu et al., 2005a; Liu et al., 2005b). 
 Human SPATA4 has been reported to localize to the nucleus in COS7 cells and to 
accelerate cell cycle progression in MCF7 cells by speeding up the transition from S-phase to 
G2-phase. Thus, it can be considered an oncogene rather than an apoptosis-promoting gene, as 




 In rats testis, SPATA4 expression varies according to the developmental stage, 
with no expression in the first month after birth and increasing levels of expression throughout 
the second month (Liu et al., 2004a). This expression pattern overlaps with the peak of increase 
in testicular volume in rats, which occurs between days 20 and 70 after birth (Gaytan et al., 
1986), and also with the development of interstitial Leydig cells, which starts after day 30 
(Christensen, 1975). 
 In mouse, SPATA4 also seems to be linked to testis development, with increasing 
expression levels from day 10 to day 14, and constant expression after that (Liu et al., 2005c). 
 More recently, SPATA4 was also found to be expressed in hypertrophic cartilage 
of femur growth plates and osteoblasts, where it promotes mineralization of the tissue by 
activating an Erk1/2 signaling cascade (Wang et al., 2011). This pattern of expression suggests 
that SPATA4 could have a role in endochondral ossification, which is particularly important for 
the formation and lengthening of long bones. In this type of ossification, cartilage is 
progressively replaced by bone tissue during pre-natal development and, at birth, there is still 
some cartilage remaining at the epiphyseal plates of the long bones, so that they can grow in 
length during childhood and early adulthood (Mackie et al., 2011). As it will be presented in 
section 6, SPATA4 interacts with the TRAPP complex and specifically with TRAPPC2, thus it 





1.5 Golgi Reassembly Stacking proteins (GRASPs) 
In order to keep the Golgi cisternae organized in stacks, mammalian cells depend 
mainly on two Golgi reassembly stacking proteins of 55 and 65 kDa, named GRASP55 and 
GRASP65, respectively. GRASPs are peripheral membrane proteins that form trans-oligomers, 
bringing together two cisternae. They also are involved in Golgi fragmentation during mitosis, 
enabling an efficient partition of the Golgi between two daughter cells (Wang and Seemann, 
2011). 
Both GRASP65 and GRASP55 have a highly conserved N-terminal GRASP 
domain composed of two PDZ subdomains, responsible for oligomerization, and a regulatory 
and less conserved C-terminal serine-proline rich domain (SPR). The SPR domain contains 
several phosphorylation sites that are targeted by mitotic kinases, allowing for the Golgi 
disassembly to be synchronized with the cell cycle  (Vinke et al., 2011). 
The two GRASP proteins have similar structure and functions, but differ in their 
localization inside the cell. GRASP65 is found mainly at the cis-Golgi, whereas GRASP55 is 
found in medial and trans-Golgi (Vinke et al., 2011). 
Aside from their roles in maintaining Golgi structure, GRASPs also participate in 
secretion of proteins containing a C-terminal valine motif (C-TVM) such as the receptors CD8α 
and Frizzled4. GRASP65 and GRASP55 sequentially bind to the C-TVM region of these 
receptors, assisting in their progression throughout the Golgi (D’Angelo et al., 2009). 
GRASP55 has also been reported to function in the activation of matrix metalloproteinases 
(MT1-MMP, MT2-MMP, MT3-MMP, MT5-MMP), extracellular enzymes that are synthesized 
as inactive zymogens and are later activated by furin. GRASP55 physically interacts with these 
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enzymes through its PDZ2 subdomain and it is supposed to act like a molecular bridge, 
connecting furin to the metalloproteinases (Roghi et al., 2010). 
Since organisms that do not possess a stacked Golgi such as S. cerevisiae have 
GRASP homologues, it is likely that their primary function is not in the formation of stacks. 
Indeed, GRASPs are involved in a non-canonical secretory route that bypasses the Golgi, called 
“unconventional secretion”. This route is thought to be associated with stress conditions and 
sometimes requires part of the molecular machinery used in early steps of autophagy, such as 
Atg1, Atg5, Atg7 and Atg8 (Manjithaya and Subramani, 2010, 2011).  
In the protozoan Dictyostellium discoideum and in the fungi S. cerevisiae and 
Pichia pastoris, GRASP homologues (GrpA and Grh1, respectively) participate in the 
unconventional secretion of acyl-CoA binding protein (AcbA/Acb1), a sporulation factor 
(Duran et al., 2010; Kinseth et al., 2007; Manjithaya et al., 2010). In Drosophila, dGRASP is 
required for the unconventional secretion of integrin α to the plasma membrane during 
epithelium development. In this case, dGRASP is no longer a Golgi protein, and localizes to the 
plasma membrane (Schotman et al., 2008). In mammals, GRASPs are required for the 
unconventional secretion of interleukin 1β (Dupont et al., 2011) and the cystic fibrosis 
transmembrane conductance receptor (CFTR), a transmembrane protein that is usually 
delivered to the plasma membrane through conventional exocytosis, but can use the 
unconventional pathway upon ER stress (Gee et al., 2011) . 
As it will be presented, both GRASP55 and GRASP65 were found to interact with 
FLJ13611, a new component of the mammalian TRAPP complex.  
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1.6 Project: Characterization of TRAPP interacting proteins FLJ13611 and 
SPATA4 
Most proteins inside the cell do not perform their functions in isolation, but interact 
with other proteins and/or protein complexes, either in a stable or in a transient manner. As a 
consequence, the functions of a given protein can be inferred from its binding partners. 
Mapping these interactions is crucial for understanding the complexity of the cell and its 
functions, including how they sense the environment and respond to it. Indeed, much effort has 
been devoted over the last 20 years to establish the “interactome” of many model organisms 
such as yeast, C. elegans and Drosophila, as well as human (Vidal et al., 2011). In order to 
better understand the functions of the mammalian TRAPP complex, we decided to characterize 
two if its interactors, FLJ13611 and SPATA4 
FLJ13611 was originally found to interact with TRAPPC3 by tandem affinity 
purification (TAP) and mass spectrometry (Gavin et al., 2002), together with AL136752.1 and 
CGI-87, that were later characterized as components of the mammalian TRAPP complex 
(TRAPPC11 and TRAPPC12, respectively (Scrivens et al., 2011)). This led us to hypothesize 
that FLJ13611 might also be a TRAPP component, and we addressed this by yeast two-hybrid, 
co-immunoprecipitation and size-exclusion chromatography.   
Since the structure of FLJ13611 is unknown and it does not show significant 
homology to any protein already crystallized, a preliminary assessment of its structure was also 
conducted by using spectroscopic methods such as circular dichroism, UV spectroscopy, and 
fluorescence spectroscopy. These techniques are frequently used for characterization of protein 
structure in solution. With the advantages of being faster, simpler, cheaper, and requiring less 
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protein than x-ray crystallography, they are often used for preliminary characterization when a 
three-dimensional structure of the protein is not available, or to determine whether recombinant 
proteins fold similarly to their endogenous counterparts (Kelly and Price, 2000). The 
methodology used for characterization of FLJ13611 is detailed in section 2, and the results are 
presented in section 3 and discussed in section 4. 
The other TRAPP interactor, SPATA4, was previously identified by our lab in a 
yeast two-hybrid screen performed by Sokunthear Hul using TRAPPC2 as the bait. I further 
characterized the TRAPPC2-SPATA4 interaction by defining the binding regions in both 
proteins through in vitro binding assays, yeast two-hybrid and co-immunoprecipitation. The 
results of this project were recently published and are presented as a separate manuscript in 




2 Materials and Methods 
 
2.1 Buffers and Solutions 
Circular dichroism buffer (CD buffer): 20 mM Tris-H2SO4 pH 7.4, 150 mM NaF. 
Column Buffer A: 20 mM Tris-HCl pH 7.4, 200 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.1 
mM AEBSF, 0.1 mM PMSF. 
Column Buffer B: 20 mM Tris-HCl pH 7.4, 200 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.1 
mM AEBSF, 0.1 mM PMSF, 25% glycerol. 
Digestion buffer A: 20 mM Tris-HCl pH 7.4, 100 mM NaCl, 1mM CaCl2. 
Digestion buffer B: 20 mM Tris-HCl pH 7.4, 100 mM NaCl, 1mM CaCl2, 10% glycerol. 
Double drop-out medium (DDO): 0.67% yeast nitrogen base, 2% dextrose, 0.08% double 
dropout mix (aminoacid mixture lacking leucine and tryptophan). 
Gel Filtration Buffer: 50 mM Tris-HCl pH 7.2, 150 mM NaCl, 0.5 mM EDTA, 1 mM DTT. 
GST elution buffer: 50 mM Tris-HCl pH 8.0, 400 mM NaCl, 15 mM glutathione 
GST lysis buffer: 50 mM Tris-HCl pH 8.0, 400 mM NaCl, 1 mM DTT, 0.1 mM AEBSF, 0.1% 
Triton X-100, 5% glycerol (v/v). 
GST wash buffer: 50 mM Tris-HCl pH 8.0, 400 mM NaCl, 1 mM DTT, 5% glycerol (v/v). 
HBS 2x: 50mM HEPES, 280mM NaCl, 1.5mM Na2HPO4, pH 7.1. 
Immunofluorescence blocking solution: 2% BSA (w/v), 2%FBS (v/v), 0.2% fish skin gelatin 
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(v/v), in PBS. 
In vitro binding buffer: 10mM HEPES pH 7.4, 25 mM NaCl, 115 mM KCl, 2 mM MgCl2, 0.1% 
Triton X-100 (v/v), 5% glycerol (v/v). 
-Leu medium: 0.67% yeast nitrogen base, 2% dextrose, 0.08% -leu dropout mix (aminoacid 
mixture lacking leucine). 
Luria Bertani broth (LB): 0.5% yeast extract (w/v), 1% tryptone (w/v), 1% NaCl (w/v). 
LB glucose: 0.5% yeast extract (w/v), 1% tryptone (w/v), 1% NaCl (w/v), 0.2% dextrose (w/v). 
Mammalian lysis buffer: 50 mM Tris-HCl pH 7.2, 150 mM NaCl, 0.5 mM EDTA, 1 mM DTT, 
1% Triton X-100 (v/v), 1 tablet of protease inhibitor cocktail per 10 mL. 
PBS: 136 mM NaCl, 2.7 mM KCl, 10.1 mM Na2HPO4, 1,8mM KH2PO4. 
PBSt: 136 mM NaCl, 2.7 mM KCl, 10.1 mM Na2HPO4, 1,8mM KH2PO4, 0.1% Tween-20 (v/v). 
Quadruple dropout medium (QDO): 0.67% yeast nitrogen base, 2% dextrose, 0.08% 
quadruple dropout mix (aminoacid mixture lacking leucine, tryptophan, histidine and adenine). 
Running Buffer: 25 mM Tris-base, 200 mM glycine, 0.1% SDS. 
Sample buffer 4x: 250 mM Tris-HCl pH 6.8, 8% SDS (w/v), 30% glycerol, 0.02% 
bromophenol blue (w/v), 5% β-Mercaptoethanol (v/v). 
Transfer Buffer: 25 mM Tris-base, 200 mM glycine, 20% methanol. 
Triple drop-out medium (TDO): 0.67% yeast nitrogen base, 2% dextrose, 0.08% triple 
dropout mix (aminoacid mixture lacking leucine, tryptophan and histidine). 
-Trp medium: 0.67% yeast nitrogen base, 2% dextrose, 0.08% -trp dropout mix (aminoacid 
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mixture lacking tryptophan). 
Yeast peptone dextrose medium (YPD): 1% yeast extract (w/v), 2% peptone (w/v), 2% 
dextrose (w/v). 
Yeast Transformation Mix: 33.3% PEG 3500 (w/v), 0.1 M LiAc, 14% boiled salmon sperm 





2.2 Oligonucleotides, strains and plasmids 
Table 2.1 Oligonucleotides used in this study 























Table 2.2 Yeast strains used in this study 
Strain Genotype Source 




Y187 MATα, ura3-52, his3-200, ade2-101, trp1-901, leu2-3, 112, met-, 

















MSB652 TRAPPC1-pGBKT7 TRP1 Ampicillin M. Sacher 
MSB601 TRAPPC1-pGADT7 LEU2 Ampicillin M. Sacher 
MSB429 TRAPPC2-pGBKT7 TRP1 Ampicillin M. Sacher 
MSB602 TRAPPC2-pGADT7 LEU2 Ampicillin M. Sacher 
MSB435 TRAPPC2L-pGBKT7 TRP1 Ampicillin M. Sacher 
MSB610 TRAPPC2L-pGADT7 LEU2 Ampicillin M. Sacher 
MSB653 TRAPPC3-pGBKT7 TRP1 Ampicillin M. Sacher 
MSB603 TRAPPC3-pGADT7 LEU2 Ampicillin M. Sacher 
MSB660 TRAPPC3L-pGBKT7 TRP1 Ampicillin M. Sacher 
MSB611 TRAPPC3L-pGADT7 LEU2 Ampicillin M. Sacher 
MSB654 TRAPPC4-pGBKT7 TRP1 Ampicillin M. Sacher 
MSB604 TRAPPC4-pGADT7 LEU2 Ampicillin M. Sacher 
MSB655 TRAPPC5-pGBKT7 TRP1 Ampicillin M. Sacher 
MSB605 TRAPPC5-pGADT7 LEU2 Ampicillin M. Sacher 
MSB656 TRAPPC6a-pGBKT7 TRP1 Ampicillin M. Sacher 
MSB606 TRAPPC6a-pGADT7 LEU2 Ampicillin M. Sacher 
MSB657 TRAPPC6b-pGBKT7 TRP1 Ampicillin M. Sacher 
MSB607 TRAPPC6b-pGADT7 LEU2 Ampicillin M. Sacher 
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MSB663 TRAPPC8-pGBKT7 TRP1 Ampicillin M. Sacher 
MSB650 TRAPPC8-pGADT7 LEU2 Ampicillin M. Sacher 
MSB993 TRAPPC9-pGBKT7 TRP1 Ampicillin M. Sacher 
MSB994 TRAPPC9-pGADT7 LEU2 Ampicillin M. Sacher 
MSB658 TRAPPC10-pGBKT7 TRP1 Ampicillin M. Sacher 
MSB608 TRAPPC10-pGADT7 LEU2 Ampicillin M. Sacher 
MSB659 TRAPPC11-pGBKT7 TRP1 Ampicillin M. Sacher 
MSB651 TRAPPC11-pGADT7 LEU2 Ampicillin M. Sacher 
MSB681 TRAPPC12-pGBKT7 TRP1 Ampicillin M. Sacher 
MSB705 TRAPPC12-pGADT7 LEU2 Ampicillin M. Sacher 
MSB661 FLJ13611-pGBKT7 TRP1 Ampicillin M. Sacher 
MSB609 FLJ13611-pGADT7 LEU2 Ampicillin M. Sacher 
MSB986 GRASP55-pGBKT7 TRP1 Ampicillin This study 
MSB1002 GRASP55-pGADT7 LEU2 Ampicillin This study 
MSB976 GRASP65-pGBKT7 TRP1 Ampicillin This study 
MSB1003 GRASP65-pGADT7 LEU2 Ampicillin This study 
MSB1163 N-GRASP65-pGBKT7 TRP1 Ampicillin This study 
MSB1164 N-GRASP65-pGADT7 LEU2 Ampicillin This study 
MSB1182 C-GRASP65-pGBKT7 TRP1 Ampicillin This study 
MSB1183 C-GRASP65-pGADT7 LEU2 Ampicillin This study 
MSB272 pGBKT7 TRP1 Kanamycin Clontech 
MSB273 pGADT7 LEU2 Ampicillin Clontech 
26 
 
Table 2.4 Plasmids used for recombinant protein production 
Bacterial 
strain 
Plasmid Tag Bacterial 
selection marker 
Source 
MSB593 pMAL c2X MBP Ampicillin NEB 
MSB596 FLJ13611-pMAL c2X MBP (N terminal) Ampicillin M.Sacher 
MSB171 pRL652 GST Ampicillin Invitrogen 
MSB1074 GRASP65-pDEST15 GST (N terminal) Ampicillin This study 
 
 
Table 2.5 Plasmids used for transfection of mammalian cells 
Bacterial 
strain 
Plasmid Epitope Bacterial 
selection marker 
Source 
MSB1031 FLJ13611-GFP GFP (N terminal) Ampicillin This study 
MSB1032 FLJ13611-V5 V5 (N terminal) Ampicillin This study 
MSB1076 GRASP55-GFP GFP (N terminal) Ampicillin This study 




2.3 Plasmid construction 
Plasmids were constructed using the Gateway 
®
 system, where the gene of interest 
is first cloned into an entry vector and then transferred to destination vectors.  
For cloning into the entry vector pDONR201, attB1 (at the 5’ end) and attB2 (at the 
3’ end) sites flanking the gene of interest were introduced by polymerase chain reaction (PCR). 
The amplification was verified by electrophoresis on 1% agarose gel, and the PCR product was 
purified using the GeneJET 
™
 PCR purification kit (Fermentas), as per manufacturer’s 
instructions. A BP recombination reaction was then carried out in 0.2 mL PCR tubes by mixing 
45 ng of pDONR201 plasmid, 45 ng of the purified PCR product, 0.5 µL of BP clonase 
™
 
enzyme mix and TE clonase buffer up to a final volume of 2.5 µL. The reactions were 
incubated at 25 °C overnight and then stored at -20 °C. Afterwards, 1 µL of the reaction was 
transformed into E. coli DH5α competent cells, and the colonies obtained were subjected to 
plasmid DNA extraction using the Plasmid DNA Miniprep kit (BioBasic), as per 
manufacturer’s instructions. The presence of the insert was confirmed by digestion with BsrGI 
and sequenced to ensure no mutations were inserted during the cloning. 
For transferring the gene of interest from pDONR201 to the various destination 
vectors (V5, GFP, GST), an LR recombination reaction was carried out in a similar manner as 
the BP reaction (45 ng of destination vector, 45 ng of pDONR201 containing the insert, 0.5 µL 
of LR clonase
™
 enzyme mix and TE clonase buffer up to a final volume of 2.5 µL; incubated at 
25 °C overnight and stored at -20 °C), and 1µL of the reaction was transformed into E. coli 




2.4 Yeast two-hybrid 
Plasmids were transformed in either MSY86 (pGADT7 plasmids) or MSY87 
(pGBKT7 plasmids), and after selection of transformants, strains were crossed in YPD plates 
and grown for 1-2 days at 30 °C. Diploids were then selected on DDO plates and used for 
spotting of serial dilutions or replica-plated onto TDO and QDO plates. 
For spotting in serial dilutions, all the strains were normalized to the same OD, and 
diluted in sterile water at 1:10, 1:100 and 1:1000 and spotted onto DDO, TDO and QDO plates. 
Each spot contained 2 µL of yeast suspension. Plates were then incubated at 30 °C and growth 
was analyzed daily. Two proteins were considered to interact if growth was more intense than 
the growth of the negative control (plasmid with gene of interest in combination with empty 
vector). 
 
2.4.1 Yeast transformation 
Cells were grown in YPD to an OD600 of 1.0, harvested by centrifugation at 3000 g 
for 5 min and washed twice in dH2O. Cells were then incubated in transformation mix at 42°C 
for 40 min. The transformation mix was removed and cells were resuspended in dH2O, and then 
plated in the appropriate selective medium. Plates were kept at 30 °C for 3-4 days and the 




2.5 Purification of recombinant protein 
 
2.5.1 MBP tagged proteins 
E. coli BL21 DE3 cells containing the plasmid pMAL C2X-FLJ (FLJ13611 fused to 
maltose binding protein (MBP) at the N-terminal portion) were grown in LB-glucose medium 
to an OD600 of 0.5, and IPTG was added to a final concentration of 1mM to induce protein 
production. Cells were grown for 16h at 25°C, harvested by centrifugation at 4000 rpm for 20 
min and resuspended in Column buffer. Cells were lysed by sonication for 2 min and the 
insoluble portion was removed by centrifugation at 20 000x g. The resulting supernatant was 
diluted 1:1 in column buffer, bound to 500uL of amylose resin for 40 min at 4°C and then 
poured into a 1.5 x 12cm chromatography column. Amylose resin was washed 5 times with 
10mL of column buffer, and the fusion protein was eluted in 500µL aliquots of column buffer 
with 10mM maltose after a 5 min incubation at room temperature. Buffer was exchanged to 
either Circular Dichroism (CD) buffer or in vitro binding buffer in a 10DG desalting column 
(Bio-Rad), and proteins were stored at -80 °C. 
 
2.5.2 GST tagged proteins 
E. coli BL21 DE3 cells were grown in LB to an OD600 of 0.5, and IPTG was added 
to a final concentration of 1mM to induce protein production. Cells were grown for 16h at 25°C, 
harvested by centrifugation at 4000 rpm for 20 min and resuspended in GST lysis buffer. Cells 
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were lysed by sonication for 2 min and the insoluble portion was removed by centrifugation at 
20 000 g. The resulting supernatant was incubated with 500 µL of glutathione sepharose beads 
for 1h at 4°C and then poured into a 1.5 x 12cm chromatography column. The beads were 
washed 5 times with 10mL of GST wash buffer, and the purified protein was eluted in 500µL 
fractions of GST elution buffer after 5 min incubation at room temperature. Buffer was 
exchanged to in vitro binding buffer in a 10DG desalting column (Bio-Rad), and proteins were 
stored at -80°C. 
 
2.6 In vitro Binding 
For in vitro binding reactions, the indicated amounts of protein were mixed in a 1.5 
mL microcentrifuge tube, and the volume was completed to 250 µL with in vitro binding buffer. 
The tubes were kept on ice for 1h to allow proteins to bind. Then, 10uL of glutathione beads 
was added to each reaction, and the tube was left to mix on a nutator for 1h hour at 4 °C. Beads 
were pelleted for 1 min at 1000 rpm in a refrigerated centrifuge (4°C), and the supernatant was 
discarded. Beads were washed three times with 250 µL of in vitro binding buffer, and the 
proteins were eluted by boiling the beads for 2 min in 25 µL of 1x Sample Buffer. Samples 
were kept at -20 °C until further procedures. 
 
2.7 Electrophoresis and Western Blotting 
Proteins were separated using SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
and transferred to PVDF membranes for 1h at 100V in cold transfer buffer. The efficiency of 
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the transfer was assessed by staining the membrane with Ponceau, which was promptly 
removed by rinsing the membrane in distilled water. Membranes were blocked in 5% skim milk 
for 1h, and then incubated with primary antibody for 1h. After washing twice for 10 min with 
PBSt, membranes were incubated with the appropriate secondary antibody (goat anti-mouse or 
goat anti-rabbit, at dilution of 1: 10,000) for 1h, and then washed 3 times for 10 min. The blots 
were incubated with ECL for two minutes and then exposed to photographic film for 1s – 10 
min. 
 
2.8 Cell Culture and knockdown 
HeLa and HEK293T cells were grown in Dulbecco’s Modified Eagle medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C in humidified incubator 
with 5% CO2. Upon 60% confluency cells were transfected with DNA using either JetPrime 
(Polyplus Transfection) or CaPO4. JetPrime was used for transfection of plasmid DNA and 
siRNA in HeLa cells, and CaPO4 was used for transfection of plasmid DNA in HEK cells. For 
transfection with CaPO4, the appropriate amount of DNA (5-10 µg of plasmid DNA per 10cm 
dish and 0.5 -1 µg per well for 6-well dishes) was diluted in 500 µL of 168 mM CaCl2 and then 
poured dropwise into 500 µL of 2x HBS, so that the final mix contained 1x HBS and 84 mM 
CaCl2. After adding the mix dropwise, the cells were returned to the incubator. The medium 
was replaced 24h after transfection, and cells were then either harvested by scraping with Lysis 
Buffer or fixed in 100% methanol at -20°C for 4 min for immunofluorescence. For cell lysates, 
protein concentration was determined using the Bradford assay (Bio-Rad Protein Assay, 
BioRad) and BSA as standard. 
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For FLJ13611 knockdown, HeLa cells were plated onto coverslips in a 6-well dish 
and transfected with 400ng of FLJ13611-V5 plasmid and 60 picomoles of siRNA using 
JetPrime. 24h after transfection cells were washed with PBS and the medium was replaced, and 
48h after transfection cells were either harvested or fixed as above. 
 
2.9 Co-immunoprecipitation 
For co-immunoprecipitation reactions, 1 µg of antibody and 0.5 mg of protein were 
mixed in a microcentrifuge tube, the volume was completed to 500 µL with mammalian lysis 
buffer and the tubes were incubated for 16h at 4°C. Then, 10 µL of previously blocked protein 
A or protein G agarose beads was added to each reaction, followed by a 2h incubation on a 
nutator at 4 °C. The beads were washed three times with 0.5 mL of mammalian lysis buffer and 
boiled in 25 µL of 1x SB for 2 min. Samples were kept at -20 °C until further procedures. 
  
2.10 Size exclusion chromatography 
HEK293T cells were harvested 48h post-transfection by scraping in mammalian 
lysis buffer. The lysates were clarified at 15 000 rpm for 15 min, protein concentration was 
determined as described above, and 2.5 mg was loaded onto a Superdex 200 column (GE 
Healthcare). The sample was fractionated in gel filtration buffer at flow rate of 0.5 mL/min, and 




2.11 Immunofluorescence and Fluorescence microscopy 
Fixed HeLa cells were incubated with immunofluorescence blocking solution for 30 
min, and then with primary antibody diluted in blocking solution (1:500) for 1h. After washing 
three times with PBS, the cells were incubated with the appropriate secondary antibody (at a 
dilution of 1:250) and DAPI (at a dilution of 1:1000) for 45 min. After three washes in PBS, 
coverslips were mounted onto a slide containing one drop of anti-fade and sealed with nail 
polish. All incubations were performed at room temperature. Pictures were taken on a Zeiss 
Axioplan epifluorescence microscope and overlayed using Adobe Photoshop. 
 
2.12 Secondary structure prediction 
Secondary structure of FLJ13611 was predicted on the online server PSIPRED 
(www.psipred.net) using PSIPRED algorithm (v 3.0) (Buchan et al., 2010). 
 
2.13 UV spectroscopy 
Absorbance at 280nm was used to determine protein concentration of FLJ13611 
and FLJ13611-MBP for circular dichroism and fluorescence spectroscopy experiments, and the 
extinction coefficients were predicted with ProtParam (Gasteiger et al., 1999) on the ExPASy 
server. Light scattering at 310-320nm was employed to monitor the presence of aggregates and 




2.14 Far UV Circular Dichroism 
Far-UV CD spectrum was acquired on a Jasco J-815 spectrophotometer with a scan 
speed of 100 nm/min, data pitch of 0.2nm, sensitivity of 100, and with 5 accumulations, at 
room temperature. Signals were recorded from 180 to 260 nm with 0.06 mg/mL of protein in a 
0.2 cm path length cell. The percentage of different secondary structure elements was 
determined using Dichroweb server, with CDSSTR algorithm, reference set 7 and scaling factor 
0.1 (Lobley et al., 2002; Sreerama and Woody, 2000; Whitmore and Wallace, 2004). 
 
2.15 Fluorescence Spectroscopy 
Intrinsic tryptophan fluorescence of FLJ13611 was measured on a Varian Cary 
Eclipse Fluorescence Spectrophotometer from 300 to 400 nm using CAT MODE with scan 
speed set to “FAST”. Ten scans were collected and averaged. Protein concentration was 0.02 
mg/mL. To analyze acrylamide quenching of tryptophan fluorescence, a stock solution of 5M 
acrylamide was prepared in column buffer and added to the protein solution up to a final 
concentration of 1.2 M. The sample was excited at 295 nm and emission spectrum was 
observed from 300 to 400 nm. Spectrum of buffer was also recorded and subtracted from all 






3.1 FLJ13611  interacts with TRAPP subunits by yeast two-hybrid 
We first checked whether FLJ13611 might be a TRAPP component by mapping its 
physical interactions with all known mammalian TRAPP subunits (C1, C2, C2L, C3, C3L, C4, 
C5, C6a, C6b, C8, C9, C10, C11 and C12) by yeast two-hybrid. FLJ13611 was crossed with 
TRAPP subunits in two orientations (FLJ13611 in pGAD x TRAPP in pGBK and FLJ13611 in 
pGBK x TRAPP in pGAD). Growth on 1mM 3-amino-1,2,4-triazole (3-AT) and quadruple 
drop-out (QDO) plates was considered as an interaction, and 1mM 3-AT was used to 
distinguish between real interactions and the false positives that arise from autoactivation of the 
reporter genes. 3-AT is a competitive inhibitor of the product of the HIS3 gene, 
imidazoleglycerol-phosphate dehydratase, an enzyme that participates in histidine biosynthesis. 
The addition of 3-AT in the medium ensures that only colonies expressing high levels of HIS3 
(or true interactions) will grow. As seen in Figure 3.1, FLJ13611interacts with C2, C2L, C6a, 
C6b, C11, C12 and with itself when in pGAD, but only with C12 and with itself when in pGBK.  
The fact that fewer interactions were seen when FLJ13611 was in pGBK could be 
attributed to a possible masking of certain regions of FLJ13611 by the fusion protein (when in 
pGBK, the gene of interest is fused to the binding domain of GAL4). Alternatively, it might 





Figure 3.1 Physical interactions of FLJ13611 with TRAPP subunits. FLJ13611 interacts with 
C2, C2L, C6a, C6b, C11, C12 and with itself. Growth on double drop-out (DDO) plates 
indicates the presence of both plasmids (pGAD and pGBK), and growth on the subsequent 
plates indicates the activation of the reporter genes. Plates were scanned after 7 days. DDO: 
double drop-out media (-leu / -trp); TDO: triple drop-out media (-leu / -trp / -his); 3-AT: 3-
amino-1, 2,4-triazole; QDO: quadruple drop-out media (-leu / -trp / -his / -ade). 
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3.2 FLJ13611 interacts with the TRAPP complex in vivo 
To confirm that the interaction seen by yeast two-hybrid also occurs in vivo, human 
embryonic kidney (HEK293T) cells were transfected with either GFP or V5 tagged FLJ13611, 
and lysates were prepared and fractionated on a Superdex 200 size exclusion column. The 
fractions were analyzed by Western Blotting. As seen in Figure 3.2 (A), both FLJ13611-V5 and 
FLJ13611-GFP are found in two pools. The high molecular weight pool (left side of the panel) 
co-fractionates with the TRAPP complex, as demonstrated by the presence of TRAPPC2 and 
TRAPPC12, whereas the lower molecular weight pool (right side of the panel) corresponds to 
presumed monomeric protein.  
Some TRAPP subunits such as TRAPPC2 and TRAPPC3 also exhibit monomeric 
pools, whereas others like TRAPPC12 appear to be mostly incorporated in the complex. While 
overexpressed FLJ13611 shows a monomeric pool, this might be an artifact of overexpression 
and not necessarily true for the endogenous FLJ13611. Since the other TRAPP components are 
not overexpressed, there is exceeding FLJ13611 that simply cannot be incorporated into 
complexes.  
Although both forms of FLJ13611 co-fractionate with the TRAPP complex, this 
result per se does not prove that it is truly part of the TRAPP complex. To examine whether 
FLJ13611 is indeed interacting with the TRAPP complex, we performed a co-
immunoprecipitation (Co-IP), using anti-V5 to precipitate FLJ13611-V5 and blotted for 
TRAPPC2. As shown in Figure 3.2 (B), TRAPPC2 is efficiently co-precipitated with FLJ13611, 







Figure 3.2 FLJ13611 co-fractionates with TRAPP subunits and co-precipitates with 
TRAPPC2. A: HEK293T cells transfected with either FLJ13611-V5 or FLJ13611-GFP were 
lysed and fractionated on a Superdex 200 column. 20 µL of each fractions was analyzed by 
Western Blotting using affinity purified anti-TRAPPC2 (1:1000 dilution), anti-TRAPPC12 
(1:1000 dilution), anti-V5 (1:000 dilution) or anti-GFP (1:2500 dilution). B: HEK293T cells 
were either transfected with FLJ13611-V5 or mock transfected (the usual volume of plasmid 
used in CaPO4 transfections was replaced by dH2O), lysed and subjected to co-
immunoprecipitation with anti-V5 (+).  A portion of lysate not treated with antibody was used 
as a negative control (-), to ensure that TRAPPC2 was not non-specifically binding to the beads 
used for the pull down. Input (total cell lysate, 50 µg) represents 10% of  the amount of protein 




3.3 FLJ13611 depletion leads to Golgi fragmentation 
In order to characterize the function of FLJ13611 we decided to perform a 
knockdown using small interfering RNA (siRNA). Presently, we do not have an antibody 
against endogenous FLJ13611, thus it was necessary to transfect the cells with FLJ13611-V5 
simultaneously, in order to demonstrate the efficiency of the knockdown (Figure 3.3 A). As 
shown in Figure 3.3 (A), two different siRNAs were tested, and siRNA1 seemed to be the most 
efficient, therefore it was used in the subsequent experiments.  After staining the Golgi with 
anti-Mannosidase II, three different morphologies were observed (compact, extended and 
punctate). As shown in Figure 3.3 (C), knockdown of FLJ13611 led to disruption of the Golgi 
in more than 50% of the cells (punctate morphology) and to a consequent decrease of the other 
two morphologies (compact and extended; the decrease of the extended morphology being 
more prominent).  
Since Golgi fragmentation occurs naturally during mitosis, it is not clear whether 
the depletion of FLJ13611 actively causes the Golgi to fragment, whether it somehow blocks 
the ER-to-Golgi transport, leading to the fragmentation, or whether it prevents its reassembly 
after mitosis. Because only the localization of mannosidase II was verified, it is also not known 
whether these Golgi fragments contain other Golgi resident proteins or whether some of them 




Figure 3.3 FLJ13611 knockdown leads to fragmentation of the Golgi. A: Demonstration of 
FLJ13611 knockdown. HeLa cells were transfected with either one of the two different siRNAs 
against FLJ13611 (siRNA1 and siRNA2), or non-specific siRNA. Protein levels were analyzed 
by Western Blotting, and tubulin was used as a loading control. B: Immunoflurescence was 
performed after treating the cells with FLJ13611-directed siRNA (KD FLJ, left panel) or non 
specific siRNA (right panel). Anti-Mannosidase II (ManII) was used as a Golgi marker and 
DAPI was used to stain the nucleus. C: Quantification of Golgi phenotypes observed in A. 





3.4 FLJ13611 interacts with GRASP55 by yeast two-hybrid 
One study that relied on expression patterns in C. elegans (Zhong and Sternberg, 
2006) predicted an interaction between the C. elegans homologue of FLJ13611 and the protein 
GRASP65. The latter protein is involved in the stacking of Golgi cisternae. This led us to 
examine whether GRASP65 and the closely-related GRASP55 interact with FLJ13611 and with 
other mammalian TRAPP components by yeast two hybrid. As shown in Figure 3.4 (A), 
GRASP55 interacts with TRAPPC6a and to a lesser extent TRAPPC6b, and also with 
FLJ13611. These interactions were only seen in one orientation. For GRASP65, no interaction 
was seen when GRASP65 was in pGAD, and a strong autoactivaction occurred when 
GRASP65 was in pGBK (see Figure 3.4 B). Therefore it was not possible assess the existence 






Figure 3.4 Physical interaction of GRASP proteins with TRAPP subunits and FLJ13611. A: 
GRASP55 interacts with C6a, C6b and FLJ13611. B: GRASP65 exhibits strong autoactivation 
when in pGBK, and no interactions are seen when in pGAD. DDO: double drop-out media (-
leu / -trp); TDO: triple drop-out media (-leu / -trp / -his); 3-AT: 3-amino-1, 2,4-triazole; QDO: 




3.5 FLJ13611 interacts with GRASP65 
Since yeast two-hybrid could not be used to assess interactions between FLJ13611 
and full length GRASP65, we decided to truncate GRASP65 in two portions, in an attempt to 
overcome the autoactivation. The two fragments (N-terminal fragment from residues 1 to 211 
and C-terminal fragment from residues 212 to 440) were cloned into yeast two-hybrid vectors 
and crossed with TRAPP subunits and FLJ13611. As shown in Figure 3.5 (A), the N-terminal 
fragment of GRASP65 interacts with FLJ13611. The C-terminal fragment still autoactivates 
(not shown).  
To further support this interaction, we performed an in vitro binding assay with full 
length GRASP65. For this study we fused FLJ13611 to maltose binding protein (MBP). 
Increasing concentrations of purified FLJ13611-MBP were incubated with either GST or 







Figure 3.5 GRASP65 interacts with FLJ13611. A: The N-terminal portion of GRASP65 
interacts with FLJ13611 by yeast two-hybrid. Serial dilutions spotted on DDO, TDO, TDO with 
1mM 3-AT and QDO. Growth on 1mM 3-AT and QDO was considered an interaction.  B: 
Binding reactions contained 0.5 µM of GST (lanes 1 to 4) or GRASP65-GST (lanes 5 to 8) and 
increasing concentrations (0, 0.5, 1 and 2 µM in lanes 1-4 and 5-8, respectively) of FLJ13611-




3.6 FLJ13611 interacts with GRASPs in vivo 
To confirm that the interaction of FLJ13611 with GRASP55 and GRASP65 occurs 
in vivo in mammalian cells, HEK293T cells were transfected with either GFP-tagged GRASP55 
or GRASP65 along with FLJ13611-V5, and a Co-IP was performed. Anti-V5 was used to 
precipitate FLJ13611-V5, and anti-GFP was used to precipitate either GRASP65 or GRASP55. 
As shown in Figure 3.6 (A), FLJ13611-V5 is efficiently precipitated with both GRASP55 and 
GRASP65, but neither GRASPs are pulled down when FLJ13611-V5 is precipitated. This may 
indicate that the epitope recognized by the anti-V5 antibody is obscured by the interaction with 
GRASP. In this case, only FLJ13611 that was not interacting with GRASP could have been 
precipitated. Moreover, TRAPPC2 did not co-precipitate with any of the GRASPs. TRAPPC2 
did, however, coprecipitate with FLJ13611, confirming once again (as in Figure 3.2) that 
FLJ13611 interacts with TRAPP. 
To address whether GRASP65 interacts with other TRAPP subunits, we performed 
other Co-IPs, precipitating TRAPPC2 and blotting for GRASP65 and precipitating GRASP65 
and blotting for TRAPPC2, TRAPPC3 and TRAPPC11. As seen in Figure 3.7, no interaction 
was detected. Therefore, GRASPs seem to interact mainly with FLJ13611 that is not 






Figure 3.6 FLJ13611 interacts with GRASP55 and GRASP65 in vivo. A: HEK293T cells 
were transfected as indicated and the lysates were subjected to immunuprecipitation with anti-
GFP or anti-V5, and blotted with anti-V5, anti-GFP or anti-TRAPPC2. IP: 
immunoprecipitation; WB: western blot. L: total cell lysate (50 µg, representing 10% of  the 
amount of protein used in the precipitation). B: HEK293T cells just prior to harvesting, 




Figure 3.7 GRASP65 does not co-precipitate with the TRAPP complex. HEK293T cells were 
transfected with GRASP65-GFP, and the lysate was subjected to immunuprecipitation with 
anti-TRAPPC2 or anti-GFP (lanes +). The negative control (lane -) consisted of the same 
lysate not treated with any antibody. The samples were blotted with anti-GFP, anti-TRAPPC2, 
anti-TRAPPC3 and anti-TRAPPC11. IP: immunoprecipitation; WB: western blot; L: total cell 




3.7 Optimization of recombinant protein purification and removal of MBP 
One way to address the function of a protein is to determine its three-dimensional 
structure and, using this information, examine the effects of mutating certain residues. 
Purification of various recombinant forms of tagged FLJ13611 resulted in unstable protein. To 
determine the best conditions for the purification of the fusion protein FLJ13611-MBP, we 
performed the purification from E. Coli BL21 DE3 cultures using either Column buffers A or B. 
Column buffer B was chosen for the subsequent experiments because, although Column buffer 
A gave a considerably higher yield, it also enhanced the presence of undesirable lower 
molecular weight components (between 60 and 50 kDa, see Figure 3.8 A and B). 
A UV absorption spectrum was recorded to determine the protein concentration and 
assess the stability of FLJ13611-MBP in column buffer B. Absorption spectra of proteins have 
a major component at 280 nm, which corresponds to mainly tryptophans (although other 
aromatic residues also contribute), and this is usually used to calculate protein concentration. In 
the region between 310 nm and 350 nm, no signal is seen if the protein is completely in solution 
(Absorbance (Abs) = 0). If the sample aggregates and the size of the particles are in the order of 
the wavelength, we have Abs above zero, but what is being observed is light scattering and not 
real absorbance. Therefore, UV absorption spectrum between 310 and 350 nm can be used to 
monitor the stability of a purified protein. This is particularly useful for proteins that tend to 
aggregate or if different buffer systems have to be used for different experiments.  
As seen in Figure 3.8 (C), FLJ13611-MBP remained stable for at least 12h at room 




Figure 3.8 Purification and stability of FLJ13611-MBP. Recombinant FLJ13611-MBP 
purified in either Column buffer A (A) or Column buffer B (B). SDS-PAGE stained with 
Coomassie Blue. E1 – E5: elutions 1 to 5. FLJ13611-MBP has a predicted molecular weight of 
86.6 kDa. C: UV spectroscopy confirms stability of FLJ13611-MBP at room temperature in 
Column buffer B. The graph shows some of the 37 scans recorded over a period of 16h. 
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Having found a buffer to keep FLJ13611-MBP stable, the next step was the 
cleavage of the MBP tag. FLJ13611-MBP was kept in Column buffer B and was immobilized 
on amylose resin and digested with FactorXa for 12h. Under these conditions, the MBP 
fragment would stay bound to the resin, while FLJ13611 would be released into the supernatant. 
As seen in Figure 3.9 (A), Column buffer B did not permit the digestion to occur, and all 
FLJ13611 remained fused to MBP. This was likely due to the high glycerol concentration 
present in Column buffer B (25%), which might have inhibited the enzymatic activity of Factor 
Xa. 
Therefore, we decided to test digestion in two other buffers (Digestion Buffers A 
and B; A being an ideal buffer for FactorXa, and B a modified version, with 10% glycerol to 
improve protein stability). Digestion Buffer A caused immediate protein precipitation, visible to 
the naked eye. Digestion Buffer B still caused some protein precipitation, which was efficiently 
removed by a 20 min centrifugation. Digestion was successfully completed after 3h incubation 
at RT + 12h incubation at 4°C (see Figure 3.9 B), with all FLJ13611-MBP cleaved (note the 
disappearance of the band at 80 kDa, which corresponds to FLJ13611-MBP, and the 
appearance of a band ~ 45 kDa, which corresponds to FLJ13611 alone.) 
Following digestion, MBP was removed by binding to amylose resin, and the 
remaining FLJ13611 was checked for aggregation. As seen in Figure 3.10, the existing 
aggregates were removed by a 20 min centrifugation. Subsequently, sample was exchanged 









Figure 3.9 Digestion of FLJ13611-MBP with FactorXa. A: digestion performed in Column 
buffer B. SDS-PAGE stained with Coomassie Blue. 1: Digested product; 2: Undigested product 
recovered from amylose resin. B: digestions performed in Digestion buffer B. Complete 
digestion of FLJ13611-MBP with FactorXa in Digestion buffer B. 1: t=0; 2: t=3h; 3: t=3h RT 
+ 12h 4°C; 4: t=4h RT + 12h 4°C; 5: FLJ13611 after MBP removal. Samples were analysed 





Figure 3.10 FLJ13611 after digestion and removal of MBP fragment. Centrifugation for 20 
min efficiently removes aggregates from the sample. Note light scattering at 310 nm before 
centrifugation (pink line), which is almost completely absent after centrifugation (green line). 




3.8 Acrylamide quenching reveals the position of tryptophan residues in 
FLJ13611 
With well-behaved, purified FLJ13611 in hand we set out to determine its structure 
by several biophysical methods. FLJ13611 presents some aromatic residues (two tryptophan 
residues at positions 281 and 352, and several tyrosine residues; Figure 3.11), which gives it 
intrinsic fluorescence and makes it suitable for fluorescence spectroscopy. 
Since all of the fluorescence experiments were conducted in Column Buffer A, this 
buffer was scanned with the same instrument settings and used as a blank. As seen in Figure 
3.12 (A), the buffer has no fluorescent component, and gives a nearly flat baseline of low 
intensity, therefore it is suitable for this type of experiment. The only peak, seen at 330 nm, is 
the Raman band, which is not real fluorescence, but represents light scattered by the H-O bond 
from the solvent water. This blank was subtracted from all spectra presented. 
The excitation (λem = 340 nm) and the emission spectra (λex = 280 nm and λe x= 
295 nm) of FLJ13611 are presented in Figure 3.12 (B and C). As expected, maximum emission 
was reached when the sample was excited at 280 nm, since this wavelength excites both 
tryptophans and tyrosines. The fluorescence intensity at λex = 295 nm is about 50% lower than 
the observed for λex = 280 nm (Figure 3.12 C), since at 295 nm only tryptophan fluorescence is 
observed (tyrosines are excluded). Because there are eleven tyrosine residues, it is not possible 
to make any assumptions about their position in FLJ13611 from the fluorescence spectrum. The 
position of tryptophans, however, can be assessed. Therefore the subsequent experiments were 






Figure 3.11 FLJ13611 amino-acid sequence. Aromatic residues are highlighted in yellow 




Tryptophan maximal emission is seen around 350 nm, and since tryptophan 
fluorescence is very sensitive to the polarity of the environment (varying from 350 nm for free 
tryptophan in solution to 308 nm for completely buried tryptophan residues; (Möller and 
Denicola, 2002)), it suggests that the tryptophan residues in FLJ13611 are in a hydrophilic 
environment. To determine tryptophan accessibility, a fluorescence quenching experiment was 
performed using acrylamide as a quencher. Acrylamide is known to quench the fluorescence of 
solvent exposed tryptophan residues, and the fraction of accessible tryptophans can be 
estimated by a modified Stern-Volmer plot (Möller and Denicola, 2002). As shown in Figure 
3.12 D, the fluorescence was efficiently quenched with acrylamide. 
The accessibility of both tryptophan residues of FLJ13611 is corroborated by the 
modified Stern-Volmer plot (see Figure 3.13). The intercept value (1.0156) indicates the 
percentage of accessible tryptophans, which in this case can be rounded to 1 (100% of the 




Figure 3.12 FLJ13611 fluorescence is quenched by acrylamide. A:. Emission spectrum of 
Column Buffer A. B: Excitation spectrum of FLJ13611. C: Emission spectra of FLJ13611 
excited at 280 nm and 295 nm. D: Emission spectra of FLJ13611 excited at 280 nm upon 
successive additions of acrylamide. Vertical arrow indicates increasing concentrations of 






Figure 3.13 Modified Stern-Volmer plot of FLJ13611 fluorescence quenching. Fo: initial 
fluorescence; F: fluorescence after acrylamide addition. 
  
y = 0,6156x + 1,0156 





















3.9 Assessment of FLJ13611 secondary structure 
Since all of the proteins that show homology to FLJ13611 have been poorly studied 
thus far, the secondary structure of FLJ13611 was predicted using the online tool PSI-PRED. 
PSI-PRED is currently the most accurate program for secondary structure prediction based on 
the amino acid sequence of a protein, and uses position-specific iterated BLAST (PSI-BLAST) 
results as an input (Buchan et al., 2010). 
As seen in Figure 3.14, the protein was predicted to be half strand and half coil, 
with no helical segments. The coil segments could be either structured loops or unordered 
segments, because PSI-PRED uses only three classes of secondary structure (helix, strand and 
coil) (Jones, 1999). In this classification, turns, high curvature bends and π helices, as well as 
the absence of a regular secondary structure (random coils) are all grouped as “coil”. 
PSI-PRED prediction was then compared with experimental data obtained by Far-
UV-CD. Since any chiral molecule can give a signal in CD, the buffer used (CD buffer) was 
scanned prior to the protein sample, to ensure it would give an acceptable baseline at the 
wavelength of interest (180 to 260 nm). As seen in Figure 3.15, the spectrum obtained for 
FLJ13611 resembles one of an alpha-helical protein, with two minima around 208 nm and 222 
nm. 
In order to make a more accurate comparison, this spectrum was analyzed in 
Dichroweb using the algorithm CDSSTR, with data points from 190 to 240 nm. This algorithm 
assigns six possible classes of secondary structure: regular α-helix (helix 1), distorted α-helix 
(helix 2), regular β-strand (strand 1), distorted β-strand (strand 2), turns (T) and unordered (U) 





Figure 3.14 Predicted secondary structure of FLJ13611 by PSI-PRED. The “pred” line 
indicates the predicted conformation for each amino acid residue (C: coil; E: strand), and the 









Figure 3.15 Far-UV CD spectrum of FLJ13611. Left: baseline spectrum in green and 
FLJ13611 spectrum in blue; middle: FLJ13611 spectrum after baseline subtraction; right: 
FLJ13611 spectrum smoothened. Average of five scans. The noisy region seen in the left 
portion of the graph is due to the high tension voltages present at lower wavelengths, and was 





The proportions for each of these types of secondary structures were calculated 
from the reconstructed CD spectrum, and are summarized on Table 3.1. The fitting of the 
reconstructed data to the experimental data is shown graphically in Figure 3.16, and is also 
represented by the normalized root mean square deviation (NRMSD) value of 0.028. The 
NRMSD can assume any value from 0 (perfect fit) to 1 (no fit), and values lower than 0.1 
indicate a reliable prediction (Kelly and Price, 2005). 
Interestingly, Dichroweb analysis revealed a helix content of 17%, which is 
completely absent in the PSI-PRED prediction. Dichroweb also gives a lower percentage for 
strands (33%), and high percentage of unordered structure (30%), along with 20% of turns. 
The differences in these estimations of the secondary structure of FLJ13611 can be 
partially explained by the different classification systems used. In PSI-PRED, everything that is 
not α-helix or β-strand is considered coil, whereas CDSSTR separates turns and unordered 
segments, and also puts single residues assigned as β-strands or α-helices in the unordered 
category. This does not explain, however, the complete absence of helices in the PSI-PRED 
prediction and it is reasonable to suspect that at least a portion of those helical segments were 
computed as coils. Since PSI-PRED is based solely on sequence information rather than 
experimental data, Dichroweb values for secondary structure elements can be considered more 





Table 3.1 Calculated secondary structure fractions for FLJ13611 using the CDSSTR algorithm 
(Dichroweb). 
 
Type of secondary 
structure 
Fraction 
Helix 1 0.08 
Helix 2 0.09 
Strand 1 0.22 












Figure 3.16 Fitting of reconstructed data generated by Dichroweb to experimental data. The 
short vertical lines indicate a good fit between the two groups of data. The fractions presented 







Here we demonstrate that the previously uncharacterized protein FLJ13611 
interacts with the mammalian TRAPP complex. The interaction was confirmed by yeast-two 
hybrid, size exclusion chromatography and co-immunoprecipitation. These results are in 
accordance with previous reports demonstrating FLJ13611 co-precipitating with  TRAPPC3, 
TRAPPC8 and TRAPPC2L (Choi et al., 2011; Gavin et al., 2002).  Moreover, our data suggest 
that FLJ13611 has a role in maintaining the Golgi structure, since its depletion by siRNA leads 
to Golgi fragmentation. A similar phenotype is seen for the knockdown of the TRAPP 
components TRAPPC2, TRAPPC2L, TRAPPC8, TRAPPC11 and TRAPPC12 (Scrivens et al., 
2009, 2011). Taken together, these results suggest that FLJ13611 is a new component of the 
mammalian TRAPP complex that we propose calling TRAPPC13. 
Unlike the yeast TRAPP complexes, mammalian TRAPP does not have a known 
architecture, and the approximate positioning of each subunit is inferred from its interactions 
with other subunits. Here we show that FLJ13611 interacts strongly with TRAPPC11 and 
TRAPPC12 by yeast two hybrid. The exact position of TRAPPC11 and TRAPPC12 in the 
complex is not known, but it is reasonable to hypothesize that FLJ13611 sits on the extremity, 
together with TRAPPC2, where it would be accessible for an interaction with non-TRAPP 
components such as GRASP55 and GRASP65. FLJ13611 also interacts with the Golgi t-
SNARE syntaxin 5 (Shahrzad, 2012, unpublished results), further supporting the idea of its 




It is still not clear what the specific role of FLJ13611 within the TRAPP complex is, 
nor if it has any function outside of the complex. A BLAST search reveals homologues of 
FLJ13611 in all animals, including model organisms (C. elegans and Drosophila), but none of 
them have been characterized yet. The only clues about its function come from protein-protein 
interaction databases.  
In C. elegans, apart from the predicted interaction with GRASP65, the FLJ13611 
homolog (C56C10.7) has been shown to physically interact with pas-4 (proteasome subunit 
alpha 4) and sdz-38 (a zinc binding protein) (Li et al., 2004) 
In Drosophila, the FLJ13611 homologue (FBgn0032204) has been found to interact 
with Tango-7 (transport and Golgi organization protein 7), snama (something that sticks like 
glue, an E3 ubiquitin ligase), CG7033 (a chaperone involved in spindle organization), rob1 
(roadblock protein, a component of cytoplasmic dynein), nonA-1 and CG2021 (both involved 
in mRNA splicing via spliceosome) (Guruharsha et al., 2011).  
Tango-7 has no apparent ortholog in S. cerevisiae, and the human ortholog, EIF3M 
(eukaryotic translation initiation factor 3 subunit M; also known as PCID1 (PCI domain 
containing protein 1)), regulates apoptosis by modulating caspase levels, a function that is 
conserved in Drosophila (Chew et al., 2009). Interestingly, this protein seems to be important 
for maintenance of Golgi structure since its depletion causes Golgi fragmentation (Bard et al., 
2006), similar to what is seen when FLJ13611 is depleted. The PCI domain present in Tango-7 
is a well conserved helical domain present in various proteins from three different complexes 
(26S Proteasome lid, COP9 signalosome and Initiation factor 3) (Pick et al., 2009). These 
complexes regulate protein life span by coupling protein synthesis and degradation in a 
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supercomplex called translasome, which contains initiation and elongation factors, ribosomal 
proteins, chaperones and other proteins involved in quality control and transport (Pick et al., 
2009; Sha et al., 2009). From the interactions found in Drosophila and C. elegans, it is tempting 
to speculate that FLJ13611 is part of the translasome, since it interacts with an initiation factor 
(Tango-7), a chaperone (CG7033), a ubiquitin ligase (snama) and a proteasome subunit (pas-4). 
One possible strategy to verify whether these interactions are conserved in mammals is a TAP 
(tandem affinity purification) pull down followed by mass spectrometry. This method has been 
used to study many different protein complexes, including TRAPP (Gavin et al., 2002; Scrivens 
et al., 2011). 
Despite the absence of sequence similarity, mammalian TRAPP subunits that form 
the core of the complex (homologs of yeast TRAPP I) have similar folds based on their three 
dimensional structure, and can be divided into two families: sedlin family (TRAPPC1, 
TRAPPC2 and TRAPPC4) and Bet3 family (TRAPPC3, TRAPPC5 and TRAPPC6) (Kim et al., 
2006). The structures of the remaining subunits have not been solved yet and therefore cannot 
be classified. However, PSI-BLAST searches reveal that some of them share some sequence 
similarity. TRAPPC11 contains non-overlapping regions of homology to TRAPPC10 and to the 
yeast subunit Trs130p. FLJ13611 has been suggested to be the mammalian homolog of the 
yeast TRAPP II specific subunit Trs65p based on small regions of sequence similarity (Choi et 
al., 2011). However, a search in the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
database reveals only two motifs in human FLJ13611: DUF974 (a highly conserved domain of 
unknown function only present in FLJ13611 and its homologs) from residues 65 to 298 and 
Transglut_C (transglutaminase family, C-terminal immunoglobulin-like domain) from residues 
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313 to 345. Interestingly, for the C. elegans homolog C56C10.7 three motifs are found: 
DUF974 from residues 67 to 288, Gryzun (one of the two conserved domains present in 
TRAPPC11) from residues 163 to 388 and Trs65, found in two shorter stretches (296 to 339 
and 349 to 400), with a considerably lower score. Therefore, the classification of FLJ13611 as 
the human homolog of Trs65p does not seem to be warranted. 
FLJ13611 interacts with GRASP55 and GRASP65, and these interactions were 
demonstrated by yeast two hybrid, co-immunoprecipitation and in vitro binding assays. The 
significance of this interaction is not clear. Since TRAPP members seem to be important for 
autophagy, FLJ13611 could be involved in autophagy-related unconventional secretion through 
its interaction with GRASPs. This hypothesis could be tested by knocking down FLJ13611 and 
verifying the secretion of one of the proteins that are known to be transported by this route in 
mammalian cells, such as IL-1β or CFTR (Dupont et al., 2011; Gee et al., 2011). 
Alternatively, GRASPs could be recruiting and / or anchoring the TRAPP complex 
on the Golgi membranes through FLJ13611, and this could be tested by depleting FLJ13611 
and / or GRASPs, and verifying how much of the TRAPP complex is still bound to membranes. 
We have begun to test this hypothesis with yeast TRAPP and the GRASP homolog Grh1p, but 
no significant difference was seen in TRAPP solubility in a Grh1p knock-out strain (data not 
shown). Since yeast do not have an FLJ13611 homolog, it would be more informative to 
perform these experiments in a mammalian model system.  
We were not able to co-precipitate GRASPs with other TRAPP subunits. 
Nevertheless, we cannot exclude the possibility that GRASPs interact with the TRAPP complex. 
Once the cells are lysed, some protein complexes do not remain stable, therefore transient or 
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weak interactions are less likely to be detected by this technique. In addition, the series of 
washing steps the samples are submitted to can also disrupt some interactions, increasing the 
chances of a false negative. 
GRASPs are phosphorylated at several sites during mitosis, which causes the Golgi 
to fragment (Duran et al., 2008; Tang et al., 2010). Membrane trafficking between ER and 
Golgi is interrupted in mitosis, and it is possible that tethering factors are also regulated during 
cell division. Thus, it would be interesting to see what happens to the TRAPP complex when 
the Golgi fragments. Does TRAPP stays as a complex or does it disassemble either partially or 
completely? If it disassembles, when does it reassemble? Nothing is known about the state of 
mammalian TRAPP during different cell cycle stages, and it is possible that GRASPs, being a 
key regulator of Golgi morphology throughout the cell cycle, also regulate tethering complexes. 
An MBP fusion of FLJ13611 proved to be an unstable protein, tending to aggregate, 
especially after cleavage of the MBP tag. MBP is known to solubilize and stabilize proteins that 
would normally form inclusion bodies, possibly acting as a chaperone and helping them to fold 
properly (Fox and Waugh, 2003). Therefore, once MBP is removed, FLJ13611 could revert to 
its original unstable state. The aggregation was partially inhibited by the addition of glycerol, a 
well-known cryoprotectant and protein stabilizer. Glycerol suppresses the conformational 
flexibility that is common to proteins in solution and causes them to aggregate, and also favors 
the assumption of more compact and rigid conformations (Sousa, 1995). We can speculate that 
the unordered regions and coils found abundantly in the secondary structure of FLJ13611 are 




FLJ13611 possesses intrinsic fluorescence due to the presence of aromatic amino 
acids. Among these, two tryptophan residues are exposed at the surface of FLJ13611 and were 
completely quenched by acrylamide. If any of these residues are involved in a protein-protein 
interaction, they could become buried in a more hydrophobic environment and therefore cause a 
shift in the emission spectra of FLJ13611. Consequently, intrinsic tryptophan fluorescence 
could be used to follow the binding of FLJ13611 to interacting partners. 
The identification of novel interactors of mammalian TRAPP such as FLJ13611 and 
SPATA4 (discussed in section 6) reinforce the complexity of transport mechanisms inside the 
cell and the need for a better understanding of the regulation of this process. Determining the 
context where TRAPP is found, its structure and the proteins with which it interacts will 
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6 A yeast two hybrid screen identifies SPATA4 as a 
TRAPP interactor (Published manuscript) 
The following manuscript was published in the journal FEBS Letters (FEBS 
Letters 585 (2011) 2676–2681), with myself and Sokunthear Hul as first authors. The 
following figures were my contribution: Figure 6.3 panels C, E, F, G, H; Figure 6.4, 
Supplemental Figure 6.5. 
 
6.1 Introduction 
The process of vesicle-mediated delivery of both membranes and proteins to 
their proper intracellular location requires many factors acting in a coordinated manner. 
Many unanswered questions remain with respect to the molecular mechanisms regulating 
these processes. 
The complexes that tether these vesicles to the acceptor compartment have 
been well-studied at the structural level [1]. One such complex called TRAPP functions 
in the early portion of the secretory pathway leading to transport to the Golgi [2]. TRAPP 
or subunits within the complex have been proposed to carry out numerous functions 
including vesicle tethering [3, 4], nucleotide exchange for several small GTPases [5-8], 
regulation of gene expression [9, 10] and to contribute to Golgi morphology [8, 11]. To 
fulfill all of these functions, the complex interacts with specific vesicle coat proteins, 
GTPases, transcription factors and likely other proteins. Curiously, a mutation in one 
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subunit called TRAPPC2 (henceforth called C2) has been tied to a skeletal defect called 
spondyloepiphyseal dysplasia tarda (SEDT) [12]. Interestingly, while most SEDT 
patients have mutations that lead to a truncated C2 protein, one patient with a D47Y 
missense mutation was identified. Since this mutation is in a region of the protein that to 
date has not been shown to interact with any other TRAPP protein, it was suggested that 
it may interfere with an interaction between TRAPP and an as yet unidentified binding 
partner [13]. 
To better understand the regulation of TRAPP, we decided to look for 
proteins that interact with C2. Using a yeast two-hybrid screen, we show that a 
spermatocyte-specific protein of unknown function called SPATA4 binds specifically to 
this subunit. SPATA4 binds to the C2 portion of a TRAPP and co-fractionates with the 
high molecular weight pool of C2. Ectopically expressed SPATA4 displays a cytosolic 
and nuclear localization. Our data suggest a role for SPATA4 in membrane traffic in 





6.2 Materials and Methods 
Materials and methods are described here as in the section “Supplemental 
Information” of the published manuscript. 
 
6.2.1 Oligonucleotides and plasmid constructs 





















pGBKT7-C2 This study 
pGBKT7-C2L This study 
pGADT7RecAB Clontech 
pGADT7RecAB- SPATA4 Clontech 
pGADT7RecAB- C3 Clontech 
pFLAGCMV6a Sigma 
pFLAGCMV6a- SPATA4 This study 
pRK5MYC Clontech 
pRK5MYC-C2 This study 
pMALc2X New England Biolabs 
pMALc2X - SPATA4 This study 
pET15b-C2 Byung-Ha Oh 
pPROEXTHa-C3  Byung-Ha Oh 
pACYCDuet1-C5 and C2 This study 
pDEST15 Invitrogen 
pCMV-(myc)3-ECT2 Alisa Piekny 





6.2.2 Yeast two hybrid screen 
The yeast two hybrid screen was performed as described in the 
Matchmaker™ Pretransformed Libraries User Manual (Clontech). Briefly, a 50 ml 
culture of the bait strain (AH109 containing pGBKT7-C2) was grown to an OD600 of 
0.8-0.9 in –Trp medium, centrifuged and resuspended in 5 ml of –Trp medium. 1 ml of 
the prey strain (Pretransformed Normalized MatchmakerTM Human Universal cDNA 
Library in Y187 (Clontech)) was added and the total volume of the culture was brought 
to 50 ml using 2x YPDA (0.1% yeast extract, 0.2% peptone, 0.2% dextrose, 0.3% L-
adenine hemisulphate). The cells were mated for 24-28 hours at 30ºC with shaking at 50 
rpm. Cells were subsequently plated on -Trp/-Leu/-His/-Ade medium (0.67% yeast 
nitrogen base, 2% dextrose, 0.08% -Trp/-Leu/-His/-Ade dropout mix) containing X-α-Gal 
and left at 30ºC for 3-8 days.  
Positive clones were tested for multiple prey plasmids by streaking on -Trp/-
Leu medium (0.67% yeast nitrogen base, 2% dextrose, 0.08% -Trp/-Leu dropout mix) 
containing X-α-Gal. One clone from the latter plate was then picked and streaked onto -
Trp/-Leu/-His medium (0.67% yeast nitrogen base, 2% dextrose, 0.08% -Trp/-Leu/-His 
dropout mix) containing X-α-Gal and 0.5 mM 3-amino-1,2,4-triazol (to prevent 
autoactivation) to verify that the phenotype was maintained. If a clone contained more 
than one prey plasmid then a mixture of blue and white colonies would result after 
streaking.  
Inserts were identified by polymerase chain reaction (PCR) amplification 
using the oligonucleotides pGAD-F-ID and pGAD-R-ID (Table 5.1) followed by 
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sequence analysis. Plasmids used in this study are listed in Table 5.2. 
 
6.2.3 Tissue culture and lysate preparation 
Human embryonic kidney 293T (HEK293T) cells were grown in Dulbecco’s 
modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (Wisent) 
and 1% penicillin/streptomycin. Transfections were carried out with 10-20 µg of DNA 
using the calcium phosphate method. Cells were harvested 48 hours post-transfection by 
scraping with lysis buffer (150 mM NaCl, 50 mM Tris pH 7.5, 1 mM EDTA,1% Triton 
X-100) with 1 mM sodium orthovanadate and protease inhibitors (Roche). For gel 
filtration, cells were collected as above using gel filtration lysis buffer (150 mM NaCl, 50 
mM Tris pH 7.2, 0.5 mM EDTA, 1 mM DTT, 1% Triton X-100) with protease inhibitor. 
 
6.2.4 Co-immunoprecipitation and gel filtration 
Samples for co-immunoprecipitation (CoIP) contained 1 mg of lysate made 
up to a total volume of 1 mL with 1x phosphate buffered saline (PBS; 8% NaCl, 0.2% 
KCl, 1.44% Na2HPO4, 0.24% KH2PO4). Immunoprecipitation was performed with 2 µg 
of rabbit anti-myc IgG (Abcam) on ice, at 4ºC for 16 hours, followed by incubation with 
10 µL of Protein A-agarose, on a nutator at 4ºC for 2 hours. Samples were washed 3x 
with 1 mL PBS and eluted by heating to 95ºC for 2 minutes with 1x SDS-PAGE sample 
buffer (SB). For Western analysis of the CoIP samples, primary antibodies used were 
monoclonal mouse anti-myc (Upstate) and monoclonal mouse anti-FLAG (Sigma) both 
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at 1:5,000 dilution. Secondary antibody used was peroxidase-labelled goat anti-mouse 
IgG (Kirkegaard & Perry Laboratories) at 1:10,000 dilution. 
For gel filtration analysis, samples (5 mg) were loaded on a SuperdexTM 200 
column (GE Healthcare) with a flow rate of 0.5 mL/min and 0.5 mL fractions were 
collected. Following fractionation, 25 µL of each sample was loaded on a SDS-PAGE gel 
for Western analysis. 
 
6.2.5 Recombinant protein preparation 
Cells were grown to an OD600 of 0.5-1.0 at 37 ºC and protein production was 
induced by the addition of 1 mM IPTG with shaking at 250 rpm at 25 ºC overnight. Cells 
were then pelleted at 4,000 rpm for 20 minutes and resuspended in 25 mL of column 
buffer (20 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 1 mM DTT) for maltose binding 
protein (MBP) fusion proteins, 30 mL lysis buffer (50 mM Tris-HCl pH 8.0; 400 mM 
NaCl; 1mM dithiothreitol (DTT), 5 mM ethylenediaminetetraacetic acid (EDTA), 5% 
gylcerol, protease inhibitors) for glutathione-S-transferase (GST) fusion proteins or 35 ml 
of lysis buffer (300 mM NaCl, 50 mM Tris-HCl pH 8.5, 9.7 mM β-mercaptoethanol, 0.5% 
glycerol, 0.1% Triton X-100, 1 mM AEBSF) for polyhistidine (His)-tagged proteins. 
Triton X-100 was added to a final concentration of 1% for GST fusion proteins and the 
cell suspensions were sonicated for 2 minutes. The resulting lysates were clarified at 




For MBP fusion protein purification, the crude extract was diluted 1:6 with 
column buffer and passed through a 500 µL bed volume of amylose resin (New England 
Biolabs). Retained proteins were washed with 5 column volumes of column buffer and 
eluted with maltose elution buffer (20 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 1 mM 
DTT, 10 mM maltose) in 1 mL fractions.  
For GST fusion protein purification, the crude extract was incubated with 
glutathione sepharose beads (GE Healthcare) for 1h at 4ºC, poured into a column and 
washed twice with 10mL of wash buffer (50mM Tris-HCl pH 8.0; 400mM NaCl, 5% 
glycerol, 1mM DTT). GST tagged proteins were eluted in 1mL fractions of elution buffer 
(50mM Tris-HCl pH 8.0; 400mM NaCl, 15mM glutathione) after a 5 minute incubation 
at room temperature. 
For His-tagged proteins, the crude extract was incubated at 4ºC on a nutator 
with 1 ml of Ni-NTA Agarose (Qiagen). The retained proteins were washed twice with 
10 mL wash buffer (50 mM Tris-HCl pH 8.5, 300 mM NaCl, 10 mM β-mercaptanol) and 
eluted with 3 mL of imidazole elution buffer (50 mM Tris pH 8.8, 200 mM NaCl, 200 
mM imidazole) in 1 mL fractions. In all cases, protein concentration was assayed using 
the BioRad Protein Assay dye-reagent as per the manufacturer’s instructions. MBP and 
GST fusion proteins were passed through a 10 DG column (BioRad) in binding buffer 
(10 mM HEPES pH 7.4, 25 mM NaCl, 115 mM KCl, 2 mM MgCl2, 0.1% Triton X-100) 




6.2.6 In vitro binding assay 
In vitro binding assays contained 0.1 µM of either MBP or MBP-SPATA4 
with increasing amounts (0, 0.05, 0.1, 0.25 µM) of either a heterotrimeric complex 
composed of C2/His-C3/C5 or a peptide comprising the two C-terminal helices of C2 
(H2/H3 C2), or 0.5 µM of either MBP or MBP-SPATA4 with increasing amounts (0, 0.1, 
0.2, 0.5 µM) of His-C2. Samples were made up to a total volume of 250 µl with 1x 
binding buffer and left on ice at 4ºC for 1 hour to allow binding. Pulldown employed 10 
µl amylose resin on a nutator for 1 hour. Samples were washed 3x with 250 µl of 1x 
binding buffer and the protein was eluted from the beads by heating to 95ºC in 25 µl of 
1x SB for 2 minutes. Western analysis used affinity purified polyclonal antibody 
recognizing C2 at a dilution of 1:10,000 or anti-GST (Sigma) at 1:10,000. 
 
6.2.7 Fluorescence microscopy 
HEK293 cells were plated on coverslips in six-well dishes and transfected 24 
hours later by the calcium phosphate method using 1.67 µg of plasmid per well. Cells 
were fixed 48 hours after transfection in 100% ice cold methanol for 4 minutes at -20ºC 
or with pre-warmed (37 ºC) 4% paraformaldehyde for 20 minutes at room temperature, 
rinsed with PBS and then incubated for 30 minutes with 0.01mg/mL 4′,6-diamidino-2-
phenylindole (DAPI). The cells were then washed two more times with PBS before 
mounting using Antifade Gold (Invitrogen) and visualized on a Zeiss Axioplan 
Fluorescence microscope using a 63x oil EC Plan-Neofluar objective. Images were 
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overlayed using Adobe Photoshop. 
 
6.2.8 Live cell imaging 
HEK293T cells were plated on 35mm dishes and transfected 24 hours later by 
the calcium phosphate method using 1µg of plasmid and visualized either 24 or 48 hours 
post-transfection. Images were captured on a Leica DMI6000 B inverted microscope 
coupled with a Hamamatsu C10600 ORCA-R2 digital camera. 
 
6.2.9 Cellular fractionation 
HEK293T cells were plated on 10 cm dishes, transfected 24 hours later by the 
calcium phosphate method with 10 µg of pGFP-SPATA4 and harvested in 1mL of PBS 
48 hours post-transfection. Cells were pelleted  for 10 min at 1500 rpm at 4°C and the 
supernatant was discarded. The cell pellet was resuspended in 1 mL of cold hypotonic 
Buffer N (10 mM HEPES pH 7.5, 2 mM MgCl2, 25 mM KCl, 1 mM DTT, 1 mM PMSF 
and  protease inhibitor cocktail) and incubated on ice for 10 min. Cells were then 
disrupted by 30 strokes with a glass Dounce homogenizer using pestle "B", and sucrose 
was added to the lysate to a final concentration of 0.22 M. Nuclei were pelleted by 
centrifugation at 1500 rpm for 10 min. and the supernatant was taken as the cytoplasmic 
fraction. Nuclei were washed twice with 400 µL of cold Buffer N containing sucrose at a 
final concentration of 250mM and resuspended in 400 µL of 1x SDS sample buffer. For 





6.3.1 Identification of SPATA4 as a C2 binding partner 
To begin to understand the regulation of the function of TRAPP, we 
undertook a yeast two-hybrid (Y2H) screen using C2 as the bait. A normalized, human 
cDNA library in prey plasmids, produced from multiple tissues, was used in the screen. 
After the initial screen, >180 potential interactors were identified. Potential interactors 
were narrowed down by all of the following methods: (i) duplicates were identified by 
colony PCR and AluI restriction analysis; (ii) plasmids were rescued and tested for 
autoactivation; (iii) plasmids were re-tested to remove false-positives. This process left 6 
potential interactors (Table 6.3) including the C3 subunit of TRAPP which was 
previously shown to directly interact with C2 [13].  
The six interactors were tested for specificity by checking their ability to 
interact with the TRAPP subunit C2L which is closely related to C2 [11]. Only SPATA4 
discriminated in its ability to bind to C2 and C2L while the remaining interactors bound 
to both proteins (Figure 6.1). For this reason, we chose to focus the remainder of this 





Table 6.3 C2 interactors identified in yeast two-hybrid screen 
 
Interactor cDNA accession number 
LAP3 - leucine 
aminopeptidase 3 
NM_015907.2 
REPS2 - RALBP1 associated 
Eps domain containing 2 
NM_001980975.1 
POSTN - periostin, osteoblast 
specific factor 
NM_006475.1 
SPATA22 - spermatogenesis 
associated 22 
NM_032598.3 
SPATA4 - spermatogenesis 
associated 4 
NM_144644.2 
TRAPPC3 - trafficking 








Figure 6.1 SPATA4 interacts with C2 by yeast two-hybrid. Yeast cells harboring C2 or 
C2L in the bait plasmid pGBKT7, or an empty bait plasmid (vector) and the prey plasmid 
pGADT7 with the inserts indicated (see Table 6.3) were grown on medium lacking 
tryptophan and leucine, lacking tryptophan, leucine and histidine with 1mM 3-amino-
1,2,4-triazol (3-AT), or lacking tryptophan, leucine, histidine and adenine with X-α-Gal. 






SPATA4 is a highly conserved protein that has been found in numerous 
species [15-19]. Human SPATA4 is 305 residues in length and contains a DUF1042 
domain of unknown function. Sequence analysis of the cDNA clone isolated in our 
screen revealed a frameshift that resulted in a 38 amino acid truncation of the protein 
from the carboxy-terminus suggesting that this region is not important for its interaction 
with C2 (see below). 
 
6.3.2 C2 and SPATA4 interact in vivo 
To confirm the Y2H results, we examined the ability of C2 and SPATA4 to 
interact in vivo. As shown in Figure 6.2 A, FLAG-SPATA4 co-precipitated with myc-C2 
(lane 4). We noted that the levels of FLAG-SPATA4 were considerably higher when the 
protein was co-expressed with myc-C2 compared to when it was expressed in its absence 
(compare lanes 1 and 2). This result was seen numerous times, however the basis for it 
remains unclear. Although an interaction between SPATA4 and C2L was not detected by 
Y2H (see above), we found that myc-C2L could also precipitate FLAG-SPATA4 (Figure 
6.2 B, lane 3). This is likely due to the fact that C2L is precipitating TRAPP which 
contains C2 [11]. FLAG-SPATA4 did not co-precipitate with myc-ECT2, a protein 
unrelated to C2 used as a negative control. Identical results were obtained when anti-
FLAG was used as the precipitating antibody. These results confirm the Y2H interaction 




Figure 6.2 SPATA4 and C2 interact in vivo. Lysates were prepared from HEK293T cells 
co-transfected with plasmids expressing: (A) lanes 1 and 4: FLAG-SPATA4 with myc-C2; 
lanes 2 and 5: FLAG-SPATA4 with pRK5MYC; lanes 3 and 6: pFLAGCMV6a with myc-
C2;  (B) lanes 1 and 3: FLAG-SPATA4 with myc-C2L; lanes 2 and 4: pFLAGCMV6a 
with myc-C2L; (C) lanes 1 and 3: FLAG-SPATA4 with myc-ECT2 (amino acids 421-883); 
lanes 2 and 4: pFLAGCMV6a with myc-ECT2 (amino acids 421-883). Samples were 
immunoprecipitated (co-IP) with rabbit anti-C2 (A) or rabbit anti-myc (B, C). 





6.3.3 SPATA4 binds to the TRAPP complex 
To further confirm the interaction between SPATA4 and C2 we performed an 
in vitro binding assay using MBP-SPATA4 and His6-C2. As shown in Figure 6.3 A, we 
were unable to detect binding between these proteins above background levels in this 
system. When the binding assay was performed using a heterotrimeric form of C2 bound 
to its neighboring subunits (C2/His-C3/C5 heterotrimer) efficient binding was readily 
seen (Figure 6.3 B). It is noteworthy that the binding to the heterotrimeric complex was 
sufficiently strong that the levels of MBP-SPATA4 were reduced 5 fold and the levels of 
the C2/His-C3/C5 were reduced two fold in the assay compared to monomeric C2. An 
interaction between glutathione-S-transferase (GST)-tagged C2L and MBP-SPATA4 
could not be detected (not shown). Interestingly, when just a heterodimer of His-C3/C5 
was used, binding of MBP- SPATA4 could be readily detected (Figure 6.3 C). These 
results suggest that SPATA4 preferentially interacts with the C2-localized portion of 
TRAPP and also recognizes a region on the C3/C5 dimer.  
Consistent with the above notion, lysates fractionated by size exclusion 
chromatography showed that FLAG-SPATA4 was found in a high molecular weight 
fraction that also contained TRAPP-associated C2 (Figure 6.3 D). Significantly, there 
was no pool of SPATA4 even in fractions that contained non-TRAPP-associated C2. This 
fractionation was not affected by co-expression of myc-C2 (not shown) except that the 
levels of SPATA4 were greater when the two proteins were co-expressed as stated above. 
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This high molecular weight pool of FLAG-SPATA4 coimmunoprecipitated with several 
TRAPP proteins (Figure 6.3 E).  Collectively, our results suggest that SPATA4 binds to 






Figure 6.3 SPATA4 binds to TRAPP. MBP or MBP-SPATA4 were subjected to an in 
vitro binding assay as described in materials and methods using amylose resin to pull 
down MBP and MBP-SPATA4 with increasing amounts of either His-C2 (A), C2/His-
C3/C5 (B) or His-C3/C5 (C). Samples were probed by western blotting using anti-C2 
(A,B) or anti-C3 (C) IgG. (D) Lysates were prepared from HEK293T cells transfected 
with a plasmid expressing FLAG-SPATA4 or myc-C2. Lysates were fractionated on a 
SuperdexTM 200 column and fractions were analyzed by western blotting using anti-myc 
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and anti-FLAG antibodies. (E) FLAG-SPATA4 fractions from (D) were untreated (lane 1) 
or immunoprecipitated with anti-C2 (lane 2), anti-C3 (lane 3) or anti-C11 (lane 4) IgG 
and probed with anti-FLAG IgG. (F) Full length C2 or the indicated fragments and 
mutants were tested for an interaction with SPATA4 by yeast two hybrid. Serial dilutions 
were spotted on medium lacking either leucine and tryptophan, leucine, tryptophan and 
histidine with 3-AT, or leucine, tryptophan, histidine and adenine. (G) MBP or MBP-
SPATA4 were subjected to an in vitro binding assay as in (A) with increasing amounts of 
GST fused to residues 91-140 of C2 (helices 2 and 3; GST-C2(H2/H3)). Samples were 
probed by western blotting using anti-GST IgG. (H) SPATA4 constructs were tested for 
interaction with C2 by yeast two hybrid (see Supplemental Figure 6.5). The SPATA4 
fragments generated are (human numbering): M1 (1-212), M2 (55-212), M3 (55-162), 





6.3.4 Defining the regions of interaction between SPATA4 and C2 
Since SPATA4 was identified through its interaction with C2, we sought to 
determine which regions of SPATA4 and C2 mediate the interaction between the proteins. 
Although largely similar, the three-dimensional crystal structure of C2 as part of the 
heterotrimeric complex differs slightly from uncomplexed C2 [13, 20]. Specifically, helix 
1 is extended in the heterotrimeric complex by incorporating additional residues on both 
the amino- and carboxy-terminal sides. We used several C2 mutants to determine 
whether SPATA4 interacts with this helix. First, the amino-terminal 91 residues of C2 
containing helix 1 (spanning residues 31-54 in C2 in the heterotrimeric complex) was 
cloned into the bait vector and tested for an interaction with SPATA4. As demonstrated 
in Figure 6.3 F, an interaction was not detected. We then mutated the highly conserved 
additional residues (31-34 and 51-55) that are incorporated into helix 1 in the 
heterotrimeric form of C2 into alanines. All of these mutant forms of C2 retained their 
ability to interact with SPATA4 (Figure 6.3 F). Finally, we found that the pathogenic 
D47Y SEDT mutation in helix 1 of C2 had no effect on binding to SPATA4 (Figure 6.3 
F). These results argue against a role for the involvement of helix 1 of C2  with SPATA4. 
We then focused our attention to the carboxy-terminal portion of C2 which contains two 
antiparallel helices called helix 2 and helix 3 (H2/H3) which were deleted in the amino-
terminal construct described above. As shown in Figure 6.3 G, GST-tagged recombinant 
H2/H3 (residues 91-140) was indeed able to bind MBP-SPATA4. Consistent with these 
results, a construct lacking the final 17 residues of C2 that represent H3 failed to interact 
with SPATA4 (Figure 6.3 F). These results suggest that the carboxy-terminal helix of C2 
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is necessary for interaction with SPATA4.  
To define the portion of SPATA4 that interacts with C2 we cloned portions of 
the protein into the prey vector and tested their ability to bind to C2 by Y2H. As shown in 
Figure 6.3 H and Supplemental Figure 6.5, deletion of the entire carboxy-terminal portion 
of the protein until the DUF1042 domain did not affect its interaction with C2. Further 
truncations into the DUF1042 domain ablated the interaction suggesting that this domain 
is required for the interaction with C2. However, the DUF1042 domain (amino acids 55-
212) alone was unable to bind to C2. When SPEF1, one of two other DUF1042-
containing proteins, was tested for binding to C2, no interaction was detected (not shown). 
These results suggest that the DUF1042 domain of SPATA4 is necessary but not 
sufficient for its interaction with C2. 
 
6.3.5 SPATA4  is found in both the cytosol and in the nucleus 
The binding of SPATA4 to TRAPP suggests that SPATA4 should be found 
in the cytosol. We tested this notion by cell fractionation and fluorescence microscopy 
using green fluorescent protein (GFP)-tagged SPATA4. Upon fractionation, a portion of 
GFP-SPATA4 was indeed found in the cytosol (Figure 6.4 A). A significant portion was 
also found in the nuclear-enriched fraction consistent with an earlier study [18]. The latter 
result was not due to cross-contamination between the nuclear and cytosolic fractions 
since the cytosolic marker (β-COP) and two TRAPP subunits, C2 and C3, were only 
detected in the cytosolic fraction (Figure 6.4 A). This result further supports the 
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interaction between C2 and SPATA4 taking place in the cytosol.  
We then sought to confirm the biochemical fractionation by fluorescence 
microscopic localization of GFP-SPATA4. When cells were visualized after fixing with 4% 
paraformaldehyde, GFP-SPATA4 displayed a nuclear localization in 89.4% of the cells 
(n=47) (Figure 6.4 B). Curiously, when cells were fixed with methanol, the localization 
of GFP-SPATA4 was cytosolic in 89.4% of the cells (n=104) with some cells displaying 
punctae (Figure 6.4 B). As neither of these results were consistent with the biochemical 
fractionation we visualized GFP-SPATA4 in live cells where no fixation method is used. 
In this case, all of the transfected cells showed the GFP-SPATA4 signal in both the 
nucleus and the cytosol (Figure 6.4 B). Although some cells showed a stronger signal in 
one of these compartments, the GFP-SPATA4 signal in those cells could also be seen in 
the other compartment. Although it remains to be shown whether GFP-SPATA4 is 






Figure 6.4 Localization of SPATA4 in HEK293T cells. (A) HEK293T cells were 
transfected with pGFP-SPATA4 and harvested 48 hours later. The cells were lysed and 
separated into cytosolic (C) and nuclear fractions (N). Aliquots were analyzed by western 
blotting using anti-GFP, anti-C2, anti-C3, anti-histone B (nuclear marker) and anti-β-
COP (cytosolic marker). (B) HEK293T cells were transfected with pGFP-SPATA4 and 
visualized after fixation with either paraformaldehyde (top row) or methanol (middle 
row). The bottom panel shows a representative image of unfixed, live cells. Cytosolic 
localization is not due to background fluorescence since there are a number of 
untransfected, non-fluorescent cells in the fields as demonstrated by the DAPI merge for 




We present evidence that SPATA4, a protein of unknown function, interacts 
specifically with a protein involved in membrane traffic. Collectively, our data implicate 
SPATA4 in a role in membrane traffic by virtue of its association with the TRAPP 
complex. It is noteworthy that a low molecular weight pool of SPATA4, similar to that of 
C2 with which it interacts, was not detected. Rather, all of the ectopically expressed, 
cytosolic SPATA4 co-fractionated with TRAPP. The fact that SPATA4 is expressed 
almost exclusively in spermatocytes, suggests that TRAPP may perform a function 
specific to these cells. Although subcellular fractionation suggested that a portion of 
SPATA4 was found in the nucleus, this pool of SPATA4 would not be seen in our gel 
filtration fractions since the protocol removes nuclei and DNA from the sample prior to 
size-exclusion chromatography. Given a previous report that C2 is found in the nucleus 
[21], we cannot rule out a SPATA4-C2 interaction taking place in this compartment. It 
should be noted, however, that the previous report was based on the fractionation of 
overexpressed C2 while our fractionation focused on the endogenous protein. In addition, 
our in vitro binding assay argues against a SPATA4 interaction with non-TRAPP-
associated C2. Although SPATA4 was identified in a yeast two hybrid screen using C2 as 
the bait, SPATA4 bound more efficiently in vitro to His-C3/C5 compared to His-C2. It is 
possible that the yeast two hybrid interaction may have been mediated by a mixed 
TRAPP complex composed of human C2 with yeast TRAPP proteins. Such a complex is 
likely produced in yeast since the human protein complements its yeast ortholog [11, 22]. 
Alternatively, the interaction in vivo is more stable than that in vitro. 
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A recent study suggests that SPATA4 is localized to the cytosol in the 
osteoblast cell line MC3T3-E1 where it interacts with and promotes the phosphorylation 
of the kinase ERK1 [23]. An earlier study reported the localization of GFP-SPATA4 to 
the nucleus [18]. Our present work shows GFP-SPATA4 localizing to and fractionating 
with both the cytosol and nucleus in live cells. Clearly, this is a dynamic protein with 
perhaps several functions. Interestingly, mutations in C2 that lead to the skeletal defect 
SEDT include carboxy-terminal truncations [24], a region we have defined as important 
for the interaction with SPATA4. The position of C2 within TRAPP and its interactions 
with neighbouring subunits leave available this carboxy-terminal helix for interactions 
with non-stably-associated members of the complex [13]. It remains to be seen whether 
ablation of the SPATA4-C2 interaction in the cytosol is a contributing factor to SEDT. 
A previous study on ectopically expressed SPATA4 in MCF7 cells showed 
that it increased their growth rate by allowing the cells to progress through S phase more 
rapidly [17]. While the mechanism for the increased growth rate of these cells is unclear, 
our present study suggests it may be due to a more active secretory pathway. 
The involvement of the DUF1042 domain in binding to C2 is interesting in 
light of the fact that this domain has been implicated in microtubule interactions [25]. 
Given that ER-derived carriers migrate along microtubule tracks [26], it is tempting to 
speculate that SPATA4 may link TRAPP to the microtubule network to facilitate 
membrane traffic in spermatocytes. Alternatively, profound changes to the cytoskeletal 
microtubule network accompany division of spermatocytes and development of 
spermatids [27]. Such changes may present special needs for membrane traffic and 
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SPATA4 would be well positioned to allow this vesicle tether to adapt to the changing 
cytoskeletal landscape. In addition, given the link between SPATA4 and ERK1, it is 
tempting to speculate that this protein of unknown function serves to link TRAPP to 
ERK1 and thus allow membrane traffic to respond to signaling events as previously 
suggested [28]. Clearly, further studies on the SPATA4 protein in an appropriate 






6.5 Supplemental material 
 
Supplemental Figure 6.5 Yeast cells harboring C2 in the bait plasmid pGBKT7 were 
transformed with the prey plasmid pGADT7 containing full-length, wild type SPATA4 
(WT) or fragments of SPATA4.  Cells were grown on medium lacking tryptophan and 
leucine, lacking tryptophan, leucine and histidine with 1mM 3-AT, or lacking tryptophan, 
leucine, histidine and adenine. The SPATA4 fragments were: M1 (1-212), M2 (55-212), 
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